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1. Introduction 
 
In the development of cancer, many genes and pathways that are needed in 
embryogenesis to successfully undergo the replication and differentiation steps 
essential to grow from the zygote to cells of various shape and function are 
reactivated. Tumour cells thus become equipped with the ability to grow in an 
uncontrolled fashion and to metastasize. Among these oncofoetal genes is the family 
coding for the high mobility group AT-hook (HMGA) proteins with its two members 
HMGA1 and HMGA2.  
The HMGA proteins belong to a group of nuclear nonhistone proteins with a size 
smaller than 30 kDa that were discovered in proteins extracted from calf thymus 
chromatin with 0.35 M NaCl. They were named in regard to their high mobility in 
polyacrylamide gel electrophoresis (PAGE) (Goodwin et al. 1977). HMGA2 was 
originally described as high-mobility group (nonhistone chromosomal) protein 
isoform I-C (HMGIC) and consists of three highly basic AT-hooks serving as 
functional domains, an acidic C-terminal domain and potential phosphorylation sites 
within the whole amino acid sequence indicating regulation possibilities (Manfioletti et 
al. 1991). It is encoded by a gene consisting of five exons mapping to chromosomal 
band 12q15 (Chau et al. 1995). HMGA2 proteins do not possess any secondary 
structure when free in solution (Cleynen and Van de Ven 2008), and specifically bind 
to the minor groove of AT-rich sequences of B-form DNA (Giancotti et al. 1991; Cui et 
al. 2005), as it was first observed for the closely related high mobility group AT-
hook 1 proteins (HMGA1, formerly known as HMGIY) (Solomon et al. 1986) 
belonging to the same gene family. As HMGA1 and HMGA2 are highly similar 
proteins carrying the same characteristic functional domains and mainly differ in the 
distance of the three AT-hooks (Cleynen and Van de Ven 2008), a similar mode of 
operation for these proteins is suggested. HMGA2 is a protein with a length of 109 
amino acids (aa) being translated from an mRNA with a length of 4150 bases. It is 
described as an architectural transcription factor that is not able to initiate 
transcription per se, but can enhance or suppress expression of targeted genes.  
Apparently, HMGA2 generally acts by several mechanisms as a regulator of gene 
expression. One of the best studied mechanisms comprises interaction of the protein 
with DNA. In this context, the AT-hooks represent the functional domain, which 
specifically bind to the minor groove of AT-rich B-form DNA sequences. As a 
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consequence, DNA is bent thus facilitating or impairing the assembly of the 
transcription initiator complex and the start of transcription. This was described for 
the binding of HMGA2 to e.g. the promoter of the ERCC1 gene (excision repair 
cross-complementing rodent repair deficiency, complementation group 1 (includes 
overlapping antisense sequence)) (Borrmann et al. 2003), or the region -400 base 
pairs (bp) to -600 bp from the transcription start site of the ATM (ataxia telangiectasia 
mutated) gene (Palmieri et al. 2011), both of which result in altered expression. 
HMGA2 binding to AT-rich sequences in the genomic DNA is not restricted to the 
promoter region alone, but can also be found in other gene-regulatory regions being 
located in for example introns, as seen in the regulation of Igf2bp2 (insulin-like growth 
factor 2 mRNA binding protein 2) (Cleynen et al. 2007). This regulation involves also 
cooperation with NF-κB (nuclear factor of kappa light polypeptide gene enhancer in 
B-cells), which binds to a consensus binding site immediately adjacent to the AT-rich 
regulatory region of HMGA2, and its binding is enhanced by attachment of HMGA2 
(Cleynen et al. 2007).  
HMGA2 does not only bind to DNA but is also able to directly interact with other 
proteins to influence gene expression which thus represents a further mechanism of 
transcriptional regulation. Again, the AT-hooks represent the functional domains of 
HMGA2 that e.g. interacts with the activated, i.e. dephosphorylated form of pRB 
(retinoblastoma protein) by binding to the N-terminal domain or the pocket region 
between amino acids 703-737 of pRB involving its second AT-hook (Fedele et al. 
2006). In consequence, HMGA2 replaces HDAC1 (histone deacetylase 1) from the 
pRB/E2F1 (E2F transcription factor 1) complex at E2F1 target promoters resulting in 
a more open chromatin structure by recruitment of acetylases and thus enhanced 
histone acetylation with initiated/increased transcription. E2F1 itself is acetylated as 
well and thus stabilised (Fedele et al. 2006). Protein-protein interaction of HMGA2 in 
DNA repair mechanisms has recently been found in the ATR (ataxia telangiectasia 
and Rad3 related)-CHEK1 (checkpoint kinase 1) pathway, as HMGA2 is involved in a 
complex with phosphorylated (p)ATR/pCHEK1, which is not altered by DNase 
digestion after co-immunoprecipitation suggesting a DNA independent complex 
(Natarajan et al. 2013). 
Concerning post-translational modifications (PTMs) of the HMGA proteins impacting 
their function, the main focus in research up to date has been set on HMGA1 that 
undergoes acetylation, phosphorylation and methylation affecting its binding 
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properties (for review see Cleynen and Van de Ven 2008). As to HMGA2, PTMs 
include phosphorylation on the SQ-motif serine 102/glutamine 103 of HMGA2’s 
carboxy-terminus by the ATM kinase that in turn results in transcriptional 
enhancement of this gene (Palmieri et al. 2011). Likewise, HMGA2 can be highly 
phosphorylated at the acidic C-terminal domain affecting its binding properties 
(Sgarra et al. 2009).  
In its function as an architectural transcription factor, HMGA2 impacts a variety of 
cellular mechanisms. Among the first ones found to be influenced by HMGA2 was 
growth, as mice carrying mutations which led to absent Hmga2 expression developed 
the so called pygmy phenotype resulting in dwarfism (Zhou et al. 1995). Vice versa, 
overexpression of a truncated Hmga2 lacking the acidic C-tail but including the three 
AT-hooks led to gigantism associated with lipomatosis in mice (Battista et al. 1999). 
In humans, HMGA2 also is involved in the determination of body height (Weedon et 
al. 2007), shown by the 12q14 microdeletion syndrome which, amongst others, is 
associated with low birth weight and short stature (Buysse et al. 2009; Lynch et al. 
2011). Different SNP (single nucleotide polymorphism) analyses identified HMGA2 as 
one of the responsible genes for the determination of adult height (Weedon et al. 
2008; Yang et al. 2010) and constitutional rearrangement of HMGA2 resulted in 
overgrowth associated with lipomas (Ligon et al. 2005). Further involvement of 
HMGA2 in cell proliferation has been revealed by its expression in preadipocytic cells 
as a response to incubation with growth factors or foetal bovine serum in 
mesenchymal cells being subjected to a mid-G1 regulation as delayed early response 
genes (Ayoubi et al. 1999).  
Hmga2 overexpression resulting in gigantism in combination with lipomatosis in mice 
(Battista et al. 1999), the pygmy phenotype displaying enormous reduction in fat 
tissue (Zhou et al. 1995), and Hmga2 expression in fat depots of mice on a high fat 
diet (Anand and Chada 2000) led to the discovery of its involvement in the 
differentiation of adipocytes (Ayoubi et al. 1999). Besides, HMGA2 is involved in the 
differentiation of other cell types such as cardiomyocytes (Monzen et al. 2008) and 
chondrocytes (Kubo et al. 2006) and impacts developmental processes like the 
formation of myotubes (Li et al. 2012). 
Furthermore, HMGA2 has been shown to influence DNA repair mechanisms, as it is 
involved in nucleotide excision repair (Borrmann et al. 2003), base excision repair, 
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(Natarajan et al. 2013) and also participates in the ATM pathway (Palmieri et al. 
2011).  
Finally, HMGA2 is involved in the maintenance of stemness of cancer stem cells 
(Dröge and Davey 2008) sustaining an undifferentiated cell state in e.g. breast 
cancer in linkage with the let-7 microRNAs (Yu et al. 2007) or miR-93 (Liu et al. 
2012), and has impact on cell senescence as well (Nishino et al. 2008; Markowski et 
al. 2011; Markowski et al. 2011; Yu et al. 2012). 
From this vast and broad range of cellular processes and functions that are 
influenced by HMGA2, it is obvious that a tight and strict regulation of its expression 
is required. Up to date, several regulatory mechanisms are known. Among the first 
ones to be discovered was the influence of the 3’UTR (3’untranslated region). 
Reporter assays showed an up to 12.7-fold decrease in luciferase activity upon 
presence of the 3’UTR pointing to a negative regulatory influence of this element, 
which was originally thought to be caused by AUUUA motives causing destabilization 
of the mRNA (Borrmann et al. 2001). It has later been shown that the HMGA2 3’UTR 
harbours seven conserved binding sites for the let-7 microRNA family which proved 
to be the underlying mechanism of this negative HMGA2 regulation (Mayr et al. 2007; 
Lee and Dutta 2007). Consistently, expression patterns of HMGA2 and let-7 during 
embryonic development are opposite to each other, i.e. HMGA2 becomes down-
regulated upon transcriptional activation and processing of MIRLET-7 (Mayr et al. 
2007). In the recent years, additional miRNA binding sites have been discovered in 
the HMGA2 3’UTR as e.g. miR-16, miR-17 (Palmieri et al. 2012), miR-23a (Lee et al. 
2011), miR-26a (Lee et al. 2011; Palmieri et al. 2012), miR-30a (Lee et al. 2011), 
miR-33a (Rice et al. 2013), miR-93 (Liu et al. 2012), miR-98 (Hebert et al. 2007), 
miR-154 (Zhu et al. 2013), miR-196a2 (Palmieri et al. 2012) as well as miR-365 (Qi et 
al. 2012). Though HMGA2 gene expression is regulated by a huge number of 
miRNAs, its expression does not only depend on this mechanism, but also has been 
shown to positively correlate to the length of a TC(n)-repeat being located 500 bp 
upstream of the initial ATG start codon (Borrmann et al. 2003; Hodge et al. 2009). So 
far, there is only one study addressing epigenetic regulation by methylation of CpG 
(cytosine phosphate guanine)-islands and surrounding SNPs of HMGA2 which 
display differential methylation in type 2 diabetes, but no association with altered 
splicing or gene function was found (Dayeh et al. 2013). 
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Generally, tumour initiation and growth is caused by one or several events that 
disturb the balanced gene expression profile and lead to proliferation and/or 
dedifferentiation of originally differentiated, resting cells. Chromosomal aberrations 
affecting the HMGA2 locus on 12q14~15 resulting in re-expression of the intrinsically 
silenced embryonic gene are well known in a variety of benign mesenchymal 
tumours. 
In lipomas, different translocations have been described affecting the HMGA2 locus. 
Herein, the breakpoint often is located in intron 3 of the HMGA2 locus (Ashar et al. 
1995) separating the 3’UTR as regulatory unit from the open reading frame (ORF), 
which leads to a lost silencing effect due to the missing miRNA binding sequence and 
hence re-expression of HMGA2 (Mayr et al. 2007). This is also true in the 
translocation t(3;12), which leads to expression of a HMGA2/LPP (LIM domain 
containing preferred translocation partner in lipoma) fusion gene (Petit et al. 1996; 
Bartuma et al. 2009). Interestingly, lipomas also display breakpoints 5’ to HMGA2 
(Nilsson et al. 2006), which is a more common feature in uterine leiomyomas (UL) 
(Quade et al. 2003), but the activating mechanism is not fully elucidated yet. 50-80 % 
of UL are cytogenetically inconspicuous, but the subgroup of tumours carrying 
translocations involving 12q14~15 accounts for approximately 27 % of tumours with 
chromosomal aberrations (Nilbert and Heim 1990). HMGA2 has been identified as 
the target of these translocations in 1995 (Schoenmakers et al. 1995). However, 
HMGA2 overexpression in UL is generally found in comparison to the matching 
myometrial tissue (Klemke et al. 2009) and the common feature of HMGA2 
overexpression in benign mesenchymal tumours suggests a crucial role for HMGA2 
in the development of these tumours.  
In malignant tumours, the underlying causes for re-expression of HMGA2 differ from 
those in benign cancer. HMGA2 is frequently overexpressed in a variety of malignant 
epithelial tumours such as e.g. non-small cell lung cancer (Meyer et al. 2007), 
colorectal cancer (Huang et al. 2009), where increasing expression is associated with 
tumour invasiveness (Rizzi et al. 2013), ovarian serous carcinoma (McMillen et al. 
2012; Hetland et al. 2012), canine prostate cancer (Winkler et al. 2007) and others. 
However, reports on chromosomal rearrangements as the reason for this differential 
expression are rare. Amplifications of the HMGA2 locus accompanied by its 
overexpression have been reported in e.g. well-differentiated liposarcomas and 
derived cell lines (Tallini et al. 2000; Trahan et al. 2006; Persson et al. 2008; 
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Pedeutour et al. 2012), in uterine leiomyosarcoma (Cho et al. 2005), in high-grade 
serous ovarian carcinoma (Helland et al. 2011) and in carcinoma ex pleomorphic 
adenoma (Persson et al. 2009).  
As expression of HMGA2 is part of the mesenchymal stem cell program, its re-
expression in adult epithelial cells can be critical by promoting epithelial-
mesenchymal transition (EMT) thus enhancing the aggressiveness and metastatic 
potential of the developing tumour (Zha et al. 2013). The pathway that seems to be 
targeted by HMGA2 enabling EMT possibly is the WNT/CTNNB1 (wingless- type 
MMTV integration site family/ catenin (cadherin-associated protein), beta 1, 88 kDa) 
pathway (Zha et al. 2012). Silencing of Hmga2 in KRAS (v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog)-transformed rat ovarian surface epithelial cells led 
to partial reversal of EMT (Schäfer and Sers 2011) and HMGA2 has been localised to 
the invasive front of tumours enhancing metastatic behaviour and invasiveness by 
supporting the canonical TGF-beta-1 (transforming growth factor beta-1) pathway via 
up-regulation of TGFR2 (transforming growth factor-beta type 2) (Morishita et al. 
2013).  
The findings that HMGA2 plays a prominent role in a variety of human and 
mammalian cancers make it a promising target in cancer therapeutic strategies. 
Therefore, it is essential to understand the main causes that underlie reactivation and 
expression in the distinct cancer types and in benign tumours. As to ULs, the 
breakpoints upstream of HMGA2 caused by the translocation t(12;14) that do not 
lead to separation of the 3’UTR from the rest of the gene are not yet fully 
characterised. Microdeletions accompanying the microscopically balanced aberration 
may thus play a role in activation of the HMGA2 gene.  
Herein, the method of array based comparative genomic hybridisation (aCGH) was 
used to identify possible loss of genetic regulatory elements being too small for 
detection in conventional cytogenetics due to limited resolution in tumours displaying 
these aberration. ACGH provides the possibility for the detection of numerical 
chromosomal aberrations as small as ~10 kb depending on the resolution of the 
array. An array with an intermediate spacing of ~8.9 kb and ~7.4 kb for RefSeq 
genes was chosen for the investigation of ULs displaying a t(12;14) assessed in 
previous conventional cytogenetic studies (Klemke et al. 2009). The objective was to 
identify microdeletions and/or amplifications accompanying the breakpoints.  
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HMGA2 usually is expressed during embryogenesis in cells without any cytogenetic 
aberrations as a part of their development and can be activated in mesenchymal cells 
by adequate stimuli such as growth factors (GFs; Ayoubi et al. 1999). However, little 
is known about the behaviour of HMGA2 in response to GFs in cancer cells, which 
was yet another focus of this thesis. The influence of GFs and foetal bovine serum 
(FBS) on HMGA2 expression was investigated in the prostate cancer cell line PC-3 to 
address the question about similarities in the up-regulation of HMGA2 in cells of 
mesenchymal origin and malignant epithelial cells. A possible correlation between 
HMGA2 expression and proliferation was investigated by real-time RT-PCR and a 
proliferation assay. The PC-3 cell line displays a moderate HMGA2 expression that 
allows for the detection of effects induced by GFs or FBS that might correlate to a 
possible increase in cell proliferation. The same issue was addressed in human 
umbilical vein endothelial cells (HUVECs) that play a role in the development of 
cancer and growth, as, with increasing size of the tumour, angiogenesis and thus the 
building of new vessels to ensure oxygen supply and nutrition of the growing 
tumourous tissue becomes necessary.  
Interestingly, the levels of HMGA2 vary between tumours of the same entity or cell 
lines derived thereof, ranging from complete abrogation to high expression and the 
mechanisms by which this is achieved might be various. The mRNA level in the 
prostate cancer cell line LNCaP is undetectable even by a sensitive method such as 
real-time RT-PCR highlighting the strict silencing of this gene in this cell line. On this 
account, the consequences of HMGA2 incubation on these cells were assessed by 
proliferation, cytotoxicity and apoptosis assays. Furthermore, different silencing 
mechanisms and their attenuation were investigated. In consideration for HMGA2 
silencing is its knock-down by let-7, so that DICER1, a protein involved in miRNA 
processing, was reduced and HMGA2 expression was measured by real-time RT-
PCR. Additionally, due to the limited data available about the methylation status of 
HMGA2, its regulation by this epigenetic mechanism is of interest in cell lines 
reflecting regulation in vivo. To identify possible influence of hypermethylation that is 
responsible for the non-expression of HMGA2, the cell line was treated with 
5-Aza-2’-deoxcytidine (5-AdC), a methyltransferase inhibiting agent that allows the 
demethylation of proliferating cells. Trichostatin A (TSA), a histone deacetylase 
inhibitor, was used to supplement the experimental setup. 
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2. Materials and methods 
 
2.1 Cell lines and primary cells 
 
The human prostate cancer cell lines PC-3 and LNCaP were obtained from Cell 
Lines Services, Eppelheim, Germany. Pooled human umbilical vein endothelial cells 
(HUVECs) were purchased from Lonza, Cologne, Germany. The MCF-7 breast 
cancer cell line was obtained from PD Dr. G. Belge (Centre for Human Genetics, 
University of Bremen, Germany).  
2.2 Tissues 
 
Tissues were taken during surgery and snap-frozen in liquid nitrogen for further 
analysis. All patients gave their written consent. 
2.3 Plasmid DNA isolation from bacterial cultures 
 
Plasmid DNA was isolated from Escherichia coli JM109 cells transformed with the 
eukaryotic expression vector pCR3.1 (Life Technologies, Darmstadt, Germany) either 
containing the human HMGA2 wild-type coding sequence (CDS) or the empty vector 
(Fedele et al. 1998). Briefly, a starter culture was prepared, allowed to grow for 6-7 h 
and used for inoculation of an overnight culture. The next morning, plasmid DNA was 
then isolated using the NucleoBond Xtra Plus EF Kit (Macherey-Nagel, Düren, 
Germany).  
2.4 Cell culture 
 
Cell lines were cultivated either in Medium 199 (Life Technologies) supplemented 
with 20 % foetal bovine serum (FBS; Life Technologies), RPMI 1640 (Life 
Technologies) supplemented with 10 % FBS, EMEM (Eagle's Minimum Essential 
Medium) containing 10% FBS (Cell Lines Services) or in DMEM (Dulbecco's Modified 
Eagle Medium)/Ham’s F12 (1:1) supplemented with 10 % FBS (Cell Lines Services). 
LNCaP cells were cultivated in RPMI 1640 with 20 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) and 0.85 g/l NaHCO3 (PAN-Biotech, Aidenbach, 
Germany) supplemented with L-Glutamine (Biochrom AG, Berlin, Germany) and 
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10 % FBS. HUVECs were maintained in endothelial growth medium (EGM)-2 
(Lonza). When grown till confluence, cells were detached using TrypLE Express (Life 
Technologies) and passaged.  
2.4.1 Stimulation with growth factors and foetal bovine serum 
 
For stimulation with growth factors or foetal bovine serum, cells were seeded in 
Multidish 6 Well Plates (Nunc, Wiesbaden, Germany) for RNA isolation or in 
Microplates 96 Well (Greiner BioOne, Frickenhausen, Germany) for proliferation 
assay and allowed to attach for 24 h. Thereafter, cells were serum starved with the 
respective medium supplemented with 1 % FBS only for another incubation period of 
24 h. Starvation medium then was replaced by medium either supplemented with 
1 % FBS (control), 10 % or 20 % FBS, 1 % FBS + 25 ng/ml FGF1 (Jena Bioscience, 
Jena, Germany) or 1 % FBS + 25 ng/ml PDGF-BB (platelet-derived growth factor 
beta polypeptide; Sigma-Aldrich, Munich, Germany) followed by incubation for 12 h 
or 24 h. Cells were then either detached for subsequent RNA isolation or, for 
proliferation assay, grown for another 24 h in a final concentration of 10 µM 5-bromo-
2-deoxyuridine (BrdU) added to the medium.  
HUVECs were seeded in EGM-2 and serum starved with endothelial basal medium 
(EBM)-2 (Lonza) supplemented with 1 % FBS (Lonza). Stimulation was done with 
EBM-2 supplemented with 1 % FBS + 25 ng/ml FGF1, FGF2 (kindly provided by the 
University of Veterinary Medicine, Hanover) or VEGFA (Promokine, Heidelberg, 
Germany). 
2.4.2 Treatment with 5-Aza-2′-Deoxycytidine and Trichostatin A 
 
For demethylation of LNCaP cells to investigate the methylation status of HMGA2, 
150,000 cells were seeded in Multidish 6 Well Plates (Nunc) the day before treatment 
and allowed to attach. 5-AdC (Merck Millipore, Darmstadt, Germany) was applied at 
a concentration of 5 µM, 10 µM or 50 µM diluted in RPMI/HEPES and incubated for 
144 h overall. After the first 72 h, medium was refreshed followed by another 72 h 
incubation period. A non-treated control and a control treated with the same amount 
of the vehicle DMSO (dimethyl sulfoxide; Sigma-Aldrich) were included. After 144 h, 
cells were lysed for subsequent RNA isolation. For simultaneous incubation of 
LNCaP cells with 5-AdC and TSA (Merck Millipore), 50 nM TSA were added 48 h 
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before cell lysis. The equivalent amount of DMSO was added to the respective 
control.  
TSA alone was added 24 h after cell seeding and incubated for 48 h followed by RNA 
isolation. 
2.4.3 Incubation of LNCaP cells with recombinant HMGA2  
 
The influence of recombinant HMGA2 (for production details, see Richter et al. 2009) 
on LNCaP cells was tested in 96 well plates. Therefore, cells were seeded (6,300 for 
cell viability and cytotoxicity, 12,500 for apoptosis detection) and grown over night. 
The next morning, growth medium was replaced by the same culture medium 
supplemented with HMGA2 in concentrations of 1 µg/ml; 10 µg/ml and 100 µg/ml. 
After 24 h and 48 h, respectively, cells were analysed following the appropriate 
protocol.  
2.4.4 Transfection with siRNA  
 
LNCaP cells were seeded in Multidish 6 Well Plates (Nunc) and allowed to attach for 
~0.5 h. Thereafter, a cocktail of four different siRNAs (Qiagen, Hilden, Germany) 
targeting DICER1 (dicer 1, ribonuclease type III) was used at a final concentration of 
2.5 nM each in combination with 4 µl RNAiMAX (Life Technologies). 72 h after 
transfection, cells were detached and 65 % of the cell suspension was seeded out 
and another transfection was performed. After another 72 h, cells were lysed in 
Qiazol (Qiagen) for subsequent miRNA isolation.  
2.4.5 Transfection with DNA 
 
LNCaP cells were transfected with a mammalian expression vector containing the 
CDS for the wild-type HMGA2 or the empty vector alone. Lipofectamine LTX Plus 
(Life Technologies) was used as transfection reagent. Briefly, cells were seeded and 
allowed to attach. Meanwhile, transfection complexes were prepared using 9.25 µl 
Lipofectamine and 2.5 µg vector DNA for transfections in 6 well plates, and adapted 
for 96 well plates for the respective viability or cytotoxicity assays. After adding the 
transfection complexes, the cells were grown for 24 h or 48 h and then lysed for RNA 
isolation or tested for vitality.  
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2.4.6 Proliferation assay (BrDU-ELISA) 
 
Proliferation of stimulated living cells was assessed using the Cell Proliferation 
ELISA, BrdU (colorimetric) kit (Roche Diagnostics, Mannheim, Germany) following 
the manufacturer’s instructions. Absorbance was measured using a Synergy HT 
Multi-Mode Microplate Reader and the corresponding KC4 software (BioTek 
Instruments, Bad Friedrichshall, Germany). Analysis was performed with Microsoft 
Excel (Microsoft, Unterschleißheim, Germany). 
2.4.7 Cell viability and cytotoxicity assays 
 
Cell viability was tested using the Cell Proliferation Reagent WST-1 (Roche 
Diagnostics) according to the manufacturer’s instructions. Cell death was measured 
using the Cytotoxicity Detection KitPLUS (LDH) (Roche Diagnostics) following the 
original protocol.  
2.4.8 Apoptosis detection assay 
 
Apoptosis in LNCaP cells incubated with recombinant HMGA2 was detected using 
the Caspase-Glo 3/7 assay (Promega, Mannheim, Germany) following the 
manufacturer’s instructions.  
2.5 RNA/miRNA isolation 
 
RNA and miRNA were isolated from tissues or cultured cells using the RNeasy Mini 
Kit (Qiagen) or the miRNeasy Mini Kit (Qiagen), respectively, according to the 
manufacturer’s instructions. The optional DNase I digestion was included into the 
protocol. 
2.6 cDNA synthesis 
 
Total RNA (250 ng) was reverse transcribed using 150 ng random hexamers (Life 
Technologies), 200 u M-MLV (Moloney Murine Leukaemia Virus)-Reverse 
Transcriptase (Life Technologies) and 40 u RNase Out (Life Technologies) following 
the manufacturer’s instructions. 
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2.7 Real time RT-PCR 
 
Real time RT-PCR was used for the quantification of mRNA amounts relative to total 
RNA. PCR was run on a 7300 Real-Time PCR system (Life Technologies) using the 
Sequence Detection Software version 1.2.3 (Life Technologies) that also served for 
analysis, as well as Excel (Microsoft). The TaqMan Universal PCR Mastermix (Life 
Technologies) was used in combination with commercial assays for HMGA2 
(Hs00171569_m1) and DICER1 (Hs00229023_m1). Hypoxanthine phosphoribosyl-
transferase 1 (HPRT1; fw5’-GGC AGT ATA ATC CAA AGA TGG TCA A-3’, rev5’-
GTC TGG CTT ATA TCC AAC ACT TCG T-3’, probe5’-6-FAM-CAA GCT TGC TGG 
TGA AAA GGA CCC C-TAMRA-3’; Biomers, Ulm, Germany) or 18S rRNA (fw5’-GGA 
TCC ATT GGA GGG CAA GT-3’, rev5’-AAT ATA CGC TAT TGG AGC TGG AAT 
TAC-3’, probe5’-6-FAM-TGC CAG CAG CCG C-MGB-3’; Life Technologies) were 
used as endogenous controls. When using 18S rRNA for normalisation of the mRNA 
amount, cDNA was diluted 1:10. 
2.8 Chromosome preparation 
 
For chromosome preparation, metaphases were arrested using 300 ng colcemid 
(Biochrom) and incubated for ~1 h at 37 °C. Cells were then detached using TrypLE 
Express (Life Technologies) and incubated in 8 ml hypotonic solution (1:7) for 
20 min. Thereafter, cells were centrifuged for 10 min at 1000 rpm. Supernatant was 
aspirated and the pellet resuspended. Fixation was done with ice cold fixative 
(methanol:acetic acid 3:1) and repeated three times.  
2.9 Giemsa banding 
 
For GTG-banding, 15 mg trypsin were dissolved in prewarmed banding buffer for 
8 min at 37 °C. Slides were then incubated for 8 sec followed by an incubation in 
1.5 % Giemsa solution prepared with 1.5 ml Giemsa, 5 ml ethanol, 10 ml Giemsa 
buffer and aqua bidest ad 100 ml for 10 min at room temperature. Washing was done 
twice in aqua bidest. Metaphases were photographed on an Axioplan microscope 
(Carl Zeiss, Jena, Germany) using BandView software (Applied Spectral Imaging, 
Edingen-Neckarhausen, Germany). 
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For Giemsa banding followed by FISH analysis, the amount of trypsin was reduced to 
10 % of the original amount. After photographing, metaphases were decoloured in 
70 % ethanol, air dried and incubated over night at 60 °C.  
2.10 Fluorescence in situ hybridisation 
  
FISH analysis was performed for the detection of the HMGA2 locus in the cell line 
PC-3 with a phage artificial chromosome (PAC) covering intron 3 (Hauke et al. 2002) 
labelled with SpectrumOrange (Abbott Molecular, Wiesbaden, Germany) and a probe 
targeting the centromeric region of chromosome 12 labelled with SpectrumGreen 
(Abbott Molecular). Probe and chromosomal DNA on a slide were co-denatured for 
3 min at 80 °C on a ThermoBrite slide processing system (Abbott Molecular). 
Hybridisation was done over night in a humidified chamber at 37 °C. The slide was 
washed in 0.1 x SSC (usb, Cleveland, USA) at 61 °C for 5 min followed by an 
increasing ethanol series and then covered with mounting medium stained with DAPI 
(Vectorlabs, Burlingame, USA) after air drying.  
Break-apart probes RP11-269K4 (AQ478964 and AZ516203, proximal) in 
combination with RP11-745O10 (AC078927, distal) or RP11-293H23 (AC012264, 
distal) were used for investigation of potential rearrangements of the HMGA2 locus in 
PC-3 cells. Chromosomal DNA was digested with 5 ng pepsin (Merck Millipore) and 
fixated with 0.1 % paraformaldehyde (Merck Millipore)/1 % PBS (phosphate buffered 
saline; Sigma-Aldrich) for 10 min. Dehydration was done in an increasing ethanol 
series. Co-denaturation of probe and chromosomal DNA was carried out for 7 min at 
77 °C. Hybridisation took place in a humidified chamber at 37 °C over night. The 
slides were washed in 0.4 x SSC/0.3 % NP-40 (Sigma-Aldrich) for 2 min at 71 °C and 
dipped briefly in 2 x SSC/0.1 % NP-40. After air drying, mounting medium with DAPI 
was applied. 
Images were captured on an Axioskop 2 plus fluorescence microscope (Zeiss, 
Göttingen, Germany) using a high performance CCD-camera and FISHView software 
(Applied Spectral Imaging). 
2.11 Spectral karyotyping 
 
Spectral karyotyping was done using the Spectral Karyotyping Human Reagent and 
the CAD-Kit (Applied Spectral Imaging) with modifications from the original protocol. 
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Trypsin digestion was skipped and chromosomes were denatured with 100 µl 
denaturation solution on a slide warmer. Metaphases were then dehydrated in an ice 
cold increasing ethanol series, as indicated by the manufacturer. Hybridisation, 
posthybridisation including the optional blocking and detection were performed 
according to the manufacturer’s protocol. 
2.12 DNA isolation 
 
DNA from uterine leiomyomas was isolated using the QIAamp DNA Mini Kit (Qiagen) 
including the optional RNase A digestion according to the manufacturer’s 
instructions.  
2.13 Array based comparative genomic hybridisation 
 
For the detection of numerical chromosomal aberrations in uterine leiomyomas, 
aCGH was performed using Human Genome 244A Microarrays (Agilent, Waldbronn, 
Germany) according to the manufacturer’s protocol. The labelling was done using the 
Genomic DNA Labelling Kit (Agilent). 
2.14 Statistical analysis 
 
Statistical analysis was done using Microsoft Excel (Microsoft, Unterschleißheim, 
Germany) and GraphPad InStat (GraphPad Software, La Jolla, CA, USA). Data were 
analysed in regard to Gaussian distribution and identical standard deviations by 
Kolmogorov and Smirnov and Bartlett tests, respectively. A One-Way ANOVA 
(analysis of variance) or, in case of a non-Gaussian distribution, a non-parametric 
Kruskal-Wallis test, were performed. 
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3. Results 
 
3.1 HMGA2 expression in response to growth factor stimulation 
 
It is well established that in mesenchymal cells HMGA2 belongs to the delayed early 
response genes whose expression can be induced upon stimulation with a variety of 
growth factors (Ayoubi et al. 1999). This is true for growths factors such as e.g. 
FGF1, FGF2, PDGF-BB as well as FBS (Ayoubi et al. 1999). In contrast, little is 
known about if HMGA2 expression can be stimulated in cells of epithelial or 
endothelial origin as well. Therefore, the prostate cancer cell line PC-3 was chosen, 
as it displays a moderate HMGA2 expression enabling the detection of significant 
changes in the HMGA2 mRNA level upon incubation with growth factors. FISH 
analyses revealed two or three copies of the HMGA2 locus per metaphase that 
mapped to a derivative chromosome t(4;12) or t(8;12). In case of three HMGA2 
copies per metaphase, the derivative t(8;12) was present twice. The derivative 
chromosomes were confirmed by SKY analysis. Stimulation with GFs (1 % FBS 
additionally supplemented either with 25 ng/ml FGF1 or PDGF-BB) as well as 
different concentrations of FBS illustrated that HMGA2 expression apparently does 
not increase in response to these incubation settings. A BrdU ELISA to assess 
proliferation revealed increased proliferation caused by the incubation for a period of 
12 h with FGF1 and PDGF-BB (statistically significant, as assessed by a one-way 
ANOVA), whereas FBS did not alter the proliferation rate of the investigated cell line. 
In contrast to the findings in mesenchymal cells, HMGA2 expression did not rise in 
response to GF incubation. 
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Abstract 
 
BACKGROUND: 
High-mobility group AT-hook 2 (HMGA2) protein acts as an oncofoetal transcriptional 
regulator. In mesenchymal tissues, its expression can be induced by a variety of 
growth factors such as fibroblast growth factor-1 (FGF1) and platelet-derived growth 
factor-BB (PDGF-BB) as well as by foetal bovine serum (FBS), thus enhancing 
proliferation. 
 
MATERIALS AND METHODS: 
To examine these effects in epithelial malignancies, we used the PC-3 prostate 
cancer cell line for assaying proliferation and HMGA2 expression in response to 
incubation with growth factors and FBS. The HMGA2 locus was investigated by 
fluorescence in situ hybridisation (FISH) for loss, amplification or re-arrangement. 
 
RESULTS: 
PC-3 is a cell line that moderately overexpresses HMGA2. None of the growth factors 
nor FBS caused significantly increased expression of HMGA2. In contrast, a 
significantly augmented proliferation rate was observed when applying FGF1 or 
PDGF-BB for 12 h. 
 
CONCLUSION: 
HMGA2 is expressed independently of external stimuli, whereas proliferation 
stimulated by growth factors is independent of further elevated HMGA2 expression. 
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3.1.2 HMGA2 expression and its correlation with proliferation in HUVECs 
as a consequence of growth factor stimulation 
 
To address the question if HMGA2 is inducible in HUVECs by GF incubation, these 
were grown after serum starvation in media supplemented with 1 % FBS and 
25 ng/ml of different GFs each, namely FGF1, FGF2 or VEGFA. The amount of 
HMGA2 was determined by real-time RT-PCR. FGF2 yielded in the highest increase 
of HMGA2 mRNA after 12 h, followed by FGF1 and VEGFA (Figure 1). A proliferation 
assay using the same settings resulted in similar findings, with the highest 
proliferation increase of ~1.9-fold induced by stimulation with FGF2, and slightly less, 
FGF1. VEGFA induced the lowest proliferation rate when compared to the negative 
control treated with 1 % FBS only, as consistent with the lowest HMGA2 expression 
level. Generally, the ranking of induced HMGA2 expression and proliferation induced 
by the GFs corresponds to each other. This finding is supported by a Pearson 
product-moment correlation coefficient (R) between HMGA2 mRNA and proliferation 
in HUVECs of 0.96 (Figure 2), pointing to a linear correlation between these factors. 
A One-Way ANOVA confirmed extremely significant differences in proliferation 
between the control grown in medium containing 1% FBS and the cells grown in 
medium supplemented with FBS and 25 ng/ml FGF2 (p<0.001), whereat proliferation 
of cells grown in medium with added VEGFA did not display a significant change. 
The difference in induced proliferation between the treatments with VEGFA and 
FGF1 was significant (p<0.05), and the difference between VEGFA and FGF2 is 
considered as highly significant (p<0.01) as well as the difference between 1 % FBS 
and FGF1. As to the differences in HMGA2 expression, statistical analysis was done 
using a Kruskal-Wallis test. The mRNA increase in cells treated with FGF1 or FGF2 
was about 2- and 2.5 fold referring to the 0 h control (p<0.01 and p<0.001, 
respectively) and the control incubated with 1% FBS (p>0.05 and p<0.01, 
respectively), whereat VEGFA only caused a non-significant ~1.4 fold increase. The 
different p-values are indicated in Figure 1 by asterisks in the respective colour 
(green for HMGA2 expression and blue for proliferation, referring to the bars’ colour). 
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Figure 1: Relative expression of HMGA2 in HUVECs and proliferation thereof after stimulation with 
GFs. As a calibrator for the mRNA level, a control taken before stimulation was used. HPRT1 served 
as endogenous control. Proliferation was calibrated against a control incubated in starvation medium, 
i.e. EBM-2 supplemented with 1 % FBS only. Asterisks indicate significant differences in HMGA2 
expression (green) and proliferation (blue).  
 
Figure 2: Correlation between proliferation and HMGA2 expression in HUVECs after stimulation with 
various GFs. 
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3.2 Array-based comparative genomic hybridisation of uterine 
leiomyomas with a t(12;14) 
 
Uterine leiomyomas frequently display a reciprocal, apparently balanced 
translocation involving the chromosomes 12 and 14. The HMGA2 gene is the target 
for this translocation on chromosome 12 (Schoenmakers et al. 1995; Ashar et al. 
1995), and RAD51B (RAD51 paralog B) is targeted on chromosome 14 
(Schoenmakers et al. 1999). The translocation evokes very high expression of 
HMGA2, but the main mechanism has not been described yet and seems to differ 
from the loss of negative regulation by the let-7 miRNA family, which is described as 
cause for HMGA2 overexpression in lipomas. The breakpoints on chromosome 12 in 
uterine leiomyomas seem to vary and are mainly located upstream of the HMGA2 
locus (Schoenberg Fejzo et al. 1996). Small deletions not visible in conventional 
cytogenetics due to their size can also allow the extrapolation of the breakpoint 
identification leading to the identification of potential regulatory sequences.  
For the analysis of the aCGH experiments, a log2-ratio ranging between -0.25 and 
0.25 was considered as balanced between tumour and reference probe, whereat a 
ratio lower than -0.25 was considered as loss in the tumour DNA, and higher than 
0.25 was classified as a gain in tumour material. A series of at least 5 consecutive 
probes was set as minimum to be considered as potential aberration.  
The experiments conducted herein led to the detection of potential deletions on 
chromosome 12 upstream of the HMGA2 locus in two of the three samples 
investigated and are possibly caused by the translocation. In UL10, this deletion is 
located approximately 1.1 Mb upstream of HMGA2 and consists of 5 probes with a 
log-ratio of smaller than -0.25 (green dots) distributed over a region of about 31 kb. In 
the other tumour, a series of 7 consecutive probes was identified ~412 kb upstream 
of HMGA2 covering a region of about 62 kb (Figure 3). In the same tumour, a region 
downstream of RAD51B on chromosome 14 with a size of about 413 kb was shown 
to be deleted. In none of the other tumours, deletions on chromosome 14 being 
potentially related to the translocation were detected (Figure 4). 
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Figure 3: Depiction of the upstream region of the HMGA2 locus on chromosome 12. Black dots 
indicate probes with a log2-ratio between -0.25 to 0.25. Green dots represent probes with a loss in 
tumour DNA, whereat red dots stand for gains in tumour DNA. Arrows indicate the deletions potentially 
related to the translocation t(12;14).  
 
 
Figure 4: The chromosomal region 14q24.1 around RAD51B. Black dots indicate probes with a 
log2-ratio between -0.25 to 0.25. Green dots represent probes with a loss in tumour DNA, whereat red 
dots stand for gains in tumour DNA. Arrows indicate the deletions potentially related to the 
translocation t(12;14).  
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3.3 Cytotoxic effects of HMGA2 and its silencing in LNCaP cells 
 
The cell line LNCaP, which was originally established from a lymph node metastasis 
of a prostate carcinoma, does not display a reliably detectable HMGA2 expression, 
despite four apparently normal chromosomes 12. As HMGA2 mainly is down-
regulated by the let-7 miRNA family, miRNA processing in this cell line was 
decreased by DICER1 knock-down to test for an inverse correlation of this miRNA 
family. Though DICER1 expression was reduced by about 60 %, HMGA2 expression 
still was undetectable by real time RT-PCR, pointing to different mechanisms in 
HMGA2 knock-down. Worthy of consideration is also DNA methylation, a mechanism 
widely used in eukaryotes. Therefore, LNCaP cells were treated for 144 h with 5-
AdC, a known methyltransferase inhibitor thus impeding methylation in proliferating 
cells and re-inducing gene expression. After 144 h of incubation with increasing 
concentrations of 5-AdC, HMGA2 expression was reliably detected in nearly all of the 
replicates with the 0.31-, 0.43- and 0.38-fold expression for 5 µM, 10 µM and 50 µM 
5-AdC, respectively. As non-treated LNCaP cells do not display detectable HMGA2 
expression, the cell line MCF-7 served for calibration. There was no huge difference 
in HMGA2 expression between the incubation with 50 µM 5-AdC and 50 µM 5-AdC + 
50 nM TSA, and incubation with 50 nM TSA alone for 48 h did not induce HMGA2 
expression. The impact of forced HMGA2 expression was then tested by transfection 
of an expression vector containing the wt HMGA2 transcript or the empty vector used 
as a control. Viability of cells transfected with the HMGA2 insert as well as those that 
obtained the empty vector alone was reduced, so that the impact of HMGA2 
expression could not be deduced. To avoid the harmful effect of transfection with the 
expression vector, the cells were incubated with increasing concentrations of 
recombinant HMGA2. Interestingly, cell viability still was reduced by HMGA2 and 
resulted in a decrease to the 0.88-, 0.73- and 0.5-fold of the non-treated control for 
24 h incubation with 1 µg/ml, 10 µg/ml and 100 µg/ml, respectively, as determined by 
WST-1 proliferation assay. Cytotoxicity assay confirmed the increasing amount of 
dead cells due to HMGA2, as measured by lactate dehydrogenase (LDH) release, 
with a proportion of dead cells of 0.05, 0.18 and 0.25. After 48 h, the amount of living 
cells decreased to the 0.82-, 0.62 and 0.66-fold, as revealed by WST-1 assay, when 
compared to the non-treated cells. LDH assay amounted to a proportion of dead cells 
of 0, 0.04 and 0.03, respectively. There was no huge induction of apoptosis after 24 h 
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HMGA2 incubation with values close to the non-treated control, as measured by 
caspase 3/7 activity, but an increased apoptosis rate was measured after 48 h. This 
effect was dose-dependent with an apoptotic rate of 1.18, 1.29, and 1.6 for 1 µg/ml, 
10 µg/ml and 100 µg/ml HMGA2, respectively. 
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Cytotoxic effects of HMGA2 and its silencing in LNCaP 
cells 
Marietta Henrike Müller, Norbert Drieschner, Sabine Bartnitzke, Tim Focken, Jörn 
Bullerdiek 
 
Abstract 
 
The high mobility group AT-hook 2 (HMGA2) gene codes for an oncofoetal protein 
whose re-expression occurs in a variety of benign and malignant neoplasias. Its 
expression is not detectable in real-time RT-PCR in LNCaP cells derived from an 
early stage prostate carcinoma, making these cells a good model to determine the 
effects of HMGA2 expression. To avoid the detected harmful effects of transfection of 
an eukaryotic expression vector, cells were incubated with recombinant HMGA2 
which resulted in reduced cell viability and an increased time- and dose-dependent 
apoptosis rate. As underlying mechanism for the lack of HMGA2 expression, the loss 
of the HMGA2 locus was excluded. Despite their role in HMGA2 regulation, miRNAs 
also seem unlikely, as DICER1 silencing did not lead to HMGA2 activation. 
Treatment with the methyltransferase inhibitor 5-aza-2’-deoxycitidine led to low 
HMGA2 mRNA detection suggesting methylation to be responsible for HMGA2 
silencing.  
 
Introduction 
 
High mobility group AT-hook 2 (HMGA2) protein is a non-histone protein highly 
expressed in various types of stem cells during mammalian embryonic/foetal growth 
but also in adult stem cells, particularly of mesenchymal origin. In the latter case, 
strong expression of HMGA2 is inducible by certain growth factors (Lanahan et al. 
1992; Ayoubi et al. 1999; Markowski et al. 2011). Besides normal development and 
differentiation, HMGA2 is abundantly expressed in a variety of human benign 
tumours mostly of mesenchymal origin due to chromosomal rearrangements 
targeting its locus at chromosomal region 12q14~15 (Schoenmakers et al. 1995; 
Ashar et al. 1995). In contrast, many malignant tumours including those from 
epithelial tissues display high expression of HMGA2 due to distinct mechanisms. 
Results 
- 37 - 
These include e.g. amplifications as present in atypical lipomatous tumours 
(Pedeutour et al. 2012), dysregulated expression of miRNAs of the let-7 family in e.g. 
serous ovarian carcinoma (Helland et al. 2011), or other miRNAs targeting the 
HMGA2 mRNA. High expression of HMGA2 occurs in a large variety of malignant 
human neoplasias as e.g. sarcomas (Zhang et al. 2014) and carcinomas (Shell et al. 
2007; Wang et al. 2011) and is associated with a poor prognosis. An increased 
metastatic potential has been associated with expression of HMGA2 in e.g. colorectal 
cancers (Wang et al. 2011), melanomas (Raskin et al. 2013), and a significant 
correlation between high HMGA2 expression and a poor prognosis for progression-
free and overall survival of the patients was also found in ovarian cancer (Shell et al. 
2007). However, the contribution of HMGA2 to malignant neoplasias is not fully 
elucidated yet, though different cellular processes were found to be impacted by 
HMGA2. HMGA2 is mainly expressed during development (Rogalla et al. 1996; 
Hirning-Folz et al. 1998) and accordingly, its re-expression in some kind of malignant 
epithelial tumours promotes epithelial-mesenchymal transition enhancing tumour 
progression and aggressiveness, as observed in e.g. human hepatocellular 
carcinoma cells (Luo et al. 2013), gastric cancer (Zha et al. 2012; Zha et al. 2013), 
squamous cell carcinomas of the oral cavity (Miyazawa et al. 2004) and in prostate 
cancer cells (Zhu et al. 2013). HMGA2 thus is able to drive tumour metastasis, as it 
was found at the invasive front of human and murine tumours of epithelial origin 
(Morishita et al. 2013). 
Accordingly, the role of HMGA2 in human malignant tumours is of interest and might 
offer a valuable therapeutic tool in treatment. It is thus essential to identify and 
elucidate the impacts of expression in epithelial tumours as well as the reasons and 
advantages for high and, in contrast, non-expression in other tumours of the same 
entity.  
Herein, the impact of HMGA2 on viability of LNCaP cells which lack any detectable 
expression of HMGA2 was addressed. HMGA2 therefore was ectopically introduced 
into LNCaP cells using a mammalian expression vector, and cells were incubated 
with the recombinant protein. Cell viability and cytotoxicity was investigated using 
WST-1 and lactate dehydrogenase (LDH) release, as well as apoptosis was 
measured by caspase-3/7 activity. Additionally, several experiments have been 
performed to address the regulation of HMGA2. We tried to reactivate HMGA2 by 
different approaches. At first, as the let-7 miRNA family is a known down-regulator of 
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HMGA2, miRNA processing was abrogated by transient silencing of DICER1 
(dicer 1, ribonuclease type III), being part of the RNA induced silencing complex 
(RISC) and involved in the maturation of miRNAs (for review see Rana 2007). It is 
known from the literature, that the cell line LNCaP displays high expression levels of 
let-7 a-c (Nadiminty et al. 2012), indicating involvement of the let-7 family in the 
silencing of HMGA2 so that DICER1 knock-down might be followed by HMGA2 
expression. Additionally, the influence of demethylation by the methyltransferase 
inhibiting agent 5-aza-2’-deoxycitidine (5-AdC) and the histone deacetylase inhibitor 
Trichostatin A (TSA) on HMGA2 expression was investigated, as there are few 
information available concerning the methylation status of the silenced HMGA2 
locus. 
 
Materials and Methods 
 
Cell culture  
LNCaP cells were cultivated in RPMI-1640 containing 0.85 g/l NaHCO3 and 
20 mM HEPES (4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid) (PAN-Biotech, 
Aidenbach, Germany) supplemented with L-glutamine (Biochrom, Berlin, Germany) 
and 10% foetal bovine serum (FBS; Life Technologies, Darmstadt, Germany) or in 
EMEM (Eagle's Minimum Essential Medium) supplemented with 10% FBS (Cell 
Lines Services) in a humidified atmosphere at 37 °C/5 % CO2. Medium was changed 
twice per week. When grown till confluence, cells were detached using TrypLE 
Express (Life Technologies) and split.  
 
Chromosome preparation 
Metaphases were arrested applying 300 ng colcemide (Biochrom) for ~1 h. After 
detaching of the cells with TrypLE Express (Life Technologies) and treatment with 
hypotonic solution (1:7), cells were fixed with methanol:acetic acid (3:1). Suspension 
was dropped on glass slides, air dried and incubated at 37 °C for at least 24 h.  
 
GTG-banding 
Metaphases were digested using 15 mg trypsin at 37 °C and stained in a 
1.5 % Giemsa solution for 10 min. After washing the slides with distilled water and air 
drying, photographs were taken on an Axioplan Microscope (Carl Zeiss, Jena, 
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Germany) using BandView software (Applied Spectral Imaging, Edingen-
Neckarhausen, Germany) that was also used for analysing the metaphases. 
 
Spectral karyotyping 
For spectral karyotyping, the protocol for the Spectral Karyotyping Human Reagent 
and CAD-Kit (Applied Spectral Imaging) was slightly modified. Trypsin digestion of 
the metaphases was skipped and chromosomal DNA was denatured using 
denaturation solution on a slide warmer with subsequent ice-cold increasing ethanol 
series. Overnight hybridisation, post-hybridisation with included slide blocking and 
detection of stained metaphases were performed as described in the original 
protocol.  
 
Fluorescence in situ hybridisation 
A phage artificial chromosome covering intron 3 of the HMGA2 locus (Hauke et al. 
2002) and a probe specific for centromere 12 (clone pBR12; both probes labelled 
using the Nick Translation Kit (Abbott Laboratories, Abbott Park, IL, USA) and 
SpectrumOrange or SpectrumGreen (Abbott Laboratories), respectively) were used 
to determine presence and number of HMGA2 alleles. Briefly, chromosomal DNA 
and labelled probes were denatured for 3 min at 80 °C followed by overnight 
hybridisation in a humidified chamber at 37 °C. Washing of the slide was done in 
0.1x SSC (standard saline citrate; USB, Cleveland, IL, USA) for 5 min at 61 °C, which 
was then rinsed three times briefly in 1x PBS solution and air dried. The slide was 
then covered with mounting medium containing DAPI (4’, 6-diamidino-2-phenylindole; 
Vectorlabs, Burlingame, CA, USA). Photographs were taken on an Axioplan 
Microscope (Carl Zeiss) using a VDS CCD - 1300 camera and FISHView software 
(Applied Spectral Imaging) for analysis.  
 
HMGA2 expression vector transfection 
For transfection of the expression vector (pCR3.1; Life Technologies) encoding for 
the wild-type HMGA2 (for vector construction, see Fedele et al. 1998), 175,000 cells 
were seeded in 6-well plates the day before transfection. Transfection complexes 
prepared of 9.25 µl Lipofectamine LTX, 2.5 µl PLUS and 2.5 µg vector DNA reagent 
(Life Technologies) were allowed to aggregate according to the manufacturer’s 
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instruction and added to the cells. Cells were harvested for RNA isolation 24 h or 
48 h after transfection.  
For cell viability assays after transfection, 6,300 cells were seeded in 96-well plates 
(Greiner Bio-One, Frickenhausen, Germany). The amount of transfection reagent 
and DNA were down-scaled appropriate to the well surface.  
 
HMGA2 incubation of LNCaP cells 
LNCaP cells were seeded in 96-well plates and grown for 24 h. The next day, 
medium was replaced by growth medium supplemented with 1, 10 or 100 µg/ml 
recombinant HMGA2 (produced as described earlier, Richter et al. 2009). Cell 
viability, apoptosis and cell death were determined by WST-1, caspase-3/7 or LDH-
assay after 24 h and 48 h.  
 
Cell viability, cytotoxicity and apoptosis assays 
Cell viability and proliferation of LNCaP cells after transfection were quantified with 
the Cell Proliferation Reagent WST-1 (Roche Diagnostics, Mannheim, Germany). 
Cell death was determined measuring the released lactate dehydrogenase (LDH) in 
the growth medium using the Cytotoxicity Detection KitPLUS (LDH)(Roche 
Diagnostics). Both kits were used according to the manufacturer’s protocol. Each 
incubation setting was tested in quadruplicates. Apoptosis was measured using the 
Caspase 3/7 Glo Assay (Promega, Mannheim, Germany) according to the 
manufacturer’s instructions. Absorbance and luminescence were measured using a 
Synergy HT microplate reader (BioTek, Bad Friedrichshall, Germany).  
 
Treatment with 5-Aza-2’-deoxycytidine with and without Trichostatin A 
For DNA demethylation in LNCaP cells, 150,000 cells were seeded in 6-well plates 
(Nunc, Wiesbaden, Germany). The next day, medium was replaced with fresh growth 
medium supplemented with 5-aza-2’-deoxycytidine (5-AdC, Merck Millipore, 
Darmstadt, Germany) at concentrations of 5 µM, 10 µM and 50 µM and cells were 
grown for 72 h. Thereafter, medium was replaced with growth medium again 
containing 5-AdC in the previous concentrations and incubated for another 72 h. 
Cells were then lysed in buffer RLT (Qiagen, Hilden, Germany). A non-treated control 
and controls grown in medium with equivalent volumes of the vehicle DMSO were 
included. The experiment was performed four times. For the combined incubation of 
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5-AdC and Trichostatin A (TSA; Merck Millipore), LNCaP cells were treated with 
50 µM 5-AdC as described above. For the last 48 h before cell harvesting with buffer 
RLT for subsequent RNA isolation, TSA was added at a final concentration of 50 nM 
to the medium. TSA alone was applied 24 h after cell seeding at 50 nM and cells 
were incubated for 48 h. Each setting was performed in duplicates.  
 
siRNA transfection 
For transfection of LNCaP cells with siRNA (short interfering RNA), 200,000 cells 
were seeded in 6-well plates (Nunc) and allowed to attach for ~0.5 h. During that 
time, transfection complexes were prepared using 4 µl Lipofectamine RNAiMAX (Life 
Technologies) and a mixture of 4 different siRNAs (Qiagen) targeting DICER1 at a 
final concentration of 10 nM (2.5 nM each). 72 h after transfection, cells were 
detached using TrypLE Express, medium was added and 65 % of the cell 
suspension was plated again followed by another transfection as prepared 
previously. After another 72 h, cells were lysed using Qiazol (Qiagen) for subsequent 
miRNA isolation.  
 
RNA/miRNA isolation from cells  
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Total RNA including the miRNA fraction was isolated 
using the miRNeasy Mini Kit (Qiagen) following the manufacturer’s protocol. The 
optional DNase I digestion was included into both protocols as described by the 
manufacturer. 
 
cDNA synthesis and real time RT-PCR 
Total RNA (250 ng) was reverse transcribed with M-MLV (Moloney Murine 
Leukaemia Virus) Reverse Transcriptase (Life Technologies) according to the 
manufacturer’s instructions using Random Hexamers (Life Technologies).  
Quantification of mRNA transcripts was carried out on a 7300 Real-Time PCR 
System (Life Technologies) with the Sequence Detection Software version 1.2.3 (Life 
Technologies). Triplicates of each sample were run using TaqMan Universal PCR 
Master Mix (Life Technologies) and commercial assays for HMGA2 
(Hs00171569_m1) and DICER1 (Hs00229023_m1; both Life Technologies). 
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) served as endogenous control 
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(with primers fw5’-GGC AGT ATA ATC CAA AGA TGG TCA A-3’, rev5’-GTC TGG 
CTT ATA TCC AAC ACT TCG T-3’, probe5’-6-FAM-CAA GCT TGC TGG TGA AAA 
GGA CCC C-TAMRA-3’; Biomers, Ulm, Germany).  
 
Results 
Transfection of mammalian expression vector results in increased cell death, 
and HMGA2 has cytotoxic and apoptotic effects on LNCaP cells. 
The absence of HMGA2 expression in LNCaP cells might indicate advantages for the 
cells not to express this gene so that consequences of re-activation are interesting. 
Therefore, cells were transfected using an expression vector coding for wild-type 
HMGA2, which caused an expression of HMGA2 that, compared to the cell line 
MCF7 serving as calibrator for HMGA2 expression, was 3,377,000- or 5,415,000-fold 
24 h or 48 h post-transfection, respectively (data not shown). The transfection 
resulted in a decrease of living LNCaP cells of approximately 40 % and 80 % after 
24 h and 48 h, respectively, as determined by WST-1 reagent (Figure 1 A+B). A 
decrease of cell viability was also detected in the control transfected with the empty 
expression vector that ranged in the same level after 48 h as the cells expressing 
HMGA2, and was about 20 % lower after 24 h. The mock control displayed slightly 
more living cells than the non-treated control. These data were confirmed when 
measuring the release of lactate dehydrogenase, as the highest amount of dead cells 
was detected in the cells that obtained the HMGA2 expression vector, directly 
followed by the ones containing the empty vector. Equivalent to the WST-1 viability 
test, less dead cells were found in the mock control. To avoid the cell damaging 
effect of DNA transfection observed, cells were incubated with increasing amounts of 
recombinant HMGA2. The cell damaging effects of HMGA2 expression were 
confirmed, as HMGA2 caused increased cell death and less viable cells (Figure 2 
A+B). This effect was dose dependent, as cell death increased with augmented 
HMGA2 concentration for the incubation with 24 h, whereat, after 48 h, the amount of 
dead cells slowly increased from 0 to 10 µg/ml, and slightly decreased again for 
100 µg/ml. There was no apoptosis inducing effect of HMGA2 after 24 h, whereat 
increased caspase-3/7 activity was detected after 48 h, which was dose dependent 
(Figure 3). 
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Figure 1: Cell viability using Cell Proliferation Reagent WST-1 after 24 h (A) and 48 h (B) after 
transfection of LNCaP cells with the expression vector pCR3.1 either containing wild-type HMGA2 or 
without insert. A mock control with transfection reagent only and a non-treated control (NTC) were 
included into the experiment. LDH indicates the proportion of dead cells relative to the NTC set as 
zero. For comparison of WST-1 assays, NTC was referred to as 1.  
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Figure 2: Cell damaging effects of HMGA2 on LNCaP cells, as determined by WST-1, LDH release 
and caspase-3/7 activity assay. Cells were incubated with increasing concentrations of HMGA2 (1, 10 
and 100 µg/ml) for 24 h (A) or 48 h (B) followed by assay performance. Absorbance was determined 
on a Synergy HT microplate reader. 
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Figure 3: Detection of apoptosis by Caspase-3/7 activity after 24 and 48 h of HMGA2 incubation, 
respectively. Luminescence was measured on a Synergy HT microplate reader. The non-treated cells 
were set as 1.  
 
Four copies of apparently normal chromosome 12 containing the HMGA2 locus 
are present in the LNCaP cell line.  
The cell line LNCaP does not display detectable HMGA2 expression, as measured 
by real time PCR. To exclude an underlying loss of the HMGA2 locus as a reason for 
this lacking expression, the cell line was analysed by conventional cytogenetics, 
SKY-FISH and FISH with probes specific for HMGA2 and centromere 12. 
Cytogenetic analysis as well as SKY revealed four copies of apparently normal 
chromosomes 12 (Figure 4 A+B). Accordingly, FISH revealed four signals for 
centromere 12 as well as for the HMGA2 locus, respectively (Figure 4C), with both 
signals co-localised on the same chromosomes.  
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Figure 4: Cytogenetic analysis of the LNCaP cells revealed four apparently normal chromosomes 12 
(A), which was confirmed by SKY-FISH analysis (B). FISH with a centromer 12 specific probe (green) 
and a probe covering intron 3 of the HMGA2 locus also resulted in the detection of four signals for 
each probe. 
 
The knock-down of DICER1 to 40 % remaining expression does not lead to 
HMGA2 expression.  
One main actor involved in HMGA2 regulation are miRNAs targeting the 3’UTR. 
Among those, the let-7 family plays a major role. The influence of miRNAs on 
HMGA2 knock-out in LNCaP cells was tested by silencing of DICER1, encoding for a 
protein essential for the maturation and processing of miRNAs. Treatment with 
DICER1 specific siRNAs resulted in an mRNA decrease of ~60 % for the target gene 
(Figure 5) compared to the non-treated control set as one, whereas the negative 
control siRNA and the mock transfection did not cause alterations on the mRNA 
level. Nevertheless, this did not lead to HMGA2 expression, as would have been 
expected.  
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Figure 5: Relative amounts of DICER1 mRNA after 144 h in LNCaP cells transfected twice with a 
cocktail of siRNAs targeting DICER1. DICER1 was reduced to a level of 40 % compared to the non 
treated control, but HMGA2 expression remained undetectable (data not shown). HPRT1 served as 
endogenous control. 
 
5-AdC in combination with or without TSA treatment leads to the activation of 
HMGA2 expression that was not induced by TSA alone.  
As disturbing of miRNA maturation did not lead to a detectable HMGA2 expression in 
this cell line, methylation and histone acetylation was considered as a potential cause 
in HMGA2 abolishment. Therefore, the cells were treated with the demethylating 
agent 5-AdC, which turned out to be able to induce HMGA2 expression. After 
treatment with concentrations of 5 µM, 10 µM and 50 µM, respectively, HMGA2 
expression became reliably detectable at a low level in the replicates in real-time 
PCR. HMGA2 expression could not be detected in the non-treated cells (Fig. 6A). 
The highest expression resulted from incubation with 10 µM 5-AdC. Incubation of 
LNCaP cells with 5-AdC combined with the histone deacetylase inhibitor TSA also 
caused expression from the former silenced HMGA2 gene (Fig. 6B). Incubation with 
TSA alone did not induce HMGA2 expression (data not shown). 
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Figure 6: A) Treatment with 5-AdC in increasing concentrations caused rising expression of HMGA2 in 
the cell line LNCaP. Presented are the mean values of four treatments. B) Relative expression of 
HMGA2 after incubation with a combination of 50 µM 5-AdC (144 h) and 50 nM TSA (48 h), as mean 
value obtained by two replicates. Controls included non-treated cells (NTC) and cells incubated in 
medium containing the same volume of the vehicle DMSO. HPRT1 served as endogenous control.  
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Discussion 
The cell line LNCaP was established from a lymph node metastasis of a prostate 
carcinoma and, despite four apparently normal chromosomes 12, does not display 
any reliably detectable HMGA2 expression. Though HMGA2 is usually inactive in 
adult tissue, it becomes reactivated in certain benign as well as malignant tumours 
(for review see Cleynen and Van de Ven 2008), but the function of HMGA2 in 
malignant tumours and its contribution to tumour growth is still not fully elucidated.  
One main factor that contributes to a poor prognosis in malignant epithelial tumours 
associated with HMGA2 (re-) activation might be due to the protein’s potential to 
drive EMT. As HMGA2 expression is mainly restricted to mesenchymal development 
and widely down-regulated in differentiated adult tissue (Rogalla et al. 1996; Hirning-
Folz et al. 1998), its re-expression in the epithelium is a critical point because 
HMGA2 regulates e.g. the transcription factors Twist1 (twist family bHLH transcription 
factor 1) and SNAI1 (snail family zinc finger 1) as regulators of EMT (Thuault et al. 
2008; Tan et al. 2012). Indeed, as HMGA2 lacks in the cell line LNCaP, it displays 
EPCAM (epithelial cell adhesion molecule) expression, whereat staining for the 
mesenchymal marker VIM (Vimentin) was negative according to its immunologic 
profile (DSMZ datasheet, retrieved from http://www.dsmz.de/catalogues/details/ 
culture/ACC-256.html).  
Interestingly, as a consequence from incubation with HMGA2, cell viability was 
reduced in a dose dependent manner, as was shown by WST-1 assay and 
measurement of LDH release, and apoptosis was found to be slightly increased after 
48 h. It is thus tempting to speculate, that HMGA2 reactivation in malignant non-
expressing cell lines might prevent tumour progression, whereat it has a favourable 
effect on viability and proliferation in benign tumours and in some kind of malignant 
neoplasias as well. In uterine leiomyomas, tumours carrying the characteristic 
translocation t(12;14) followed by high expression of HMGA2 are even larger when 
compared to those not displaying this chromosomal aberration (Rein et al. 1998; 
Hennig et al. 1999), underlining the significance of HMGA2 in growth and 
proliferation. Despite a proliferation promoting role in other cell types, especially 
those of mesenchymal origin as e.g. chondrocytes and adipose-derived stem cells 
(Richter et al. 2009; Richter et al. 2011) but also in malignant tumour cells, such as 
those from retinoblastoma (Venkatesan et al. 2012), in liver cancer (Di Fazio et al. 
2012) and others, this effect was not observed in LNCaP cells. Instead, HMGA2 in 
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the cell line LNCaP even impedes proliferation and increases cell death, which is in 
contrast to the finding by Peng et al. (2008) that ectopic expression of HMGA2 
promotes proliferation. Instead, cell viability decreased upon incubation with 
recombinant HMGA2 and the relative amount of dead cells increased. In rat 
Dunning G cells lacking endogenous HMGA2, ectopic HMGA2 expression did not 
alter the growth ability significantly (Diana et al. 2005). The reason for the cytotoxic 
effect of HMGA2 in LNCaP cells described herein and its slight promotion of 
apoptosis after 48 h are unclear. HMGA2 has been shown to enhance genotoxic 
stress by consistent phosphorylation of the histone H2AX at Serine 139 (γ-H2AX), 
which is a hallmark of DNA double strand breaks (Boo et al. 2005). In cells with 
ectopic HMGA2 expression as well as in those endogenously expressing HMGA2, a 
higher basal γ-H2AX level and delayed γ-H2AX clearance after x-ray exposure 
resembling the phenotype of DNA-PK deficient cells with perturbed nonhomologous 
end joining repair occurs (Li et al. 2009). HMGA2 might thus reinforce the apoptosis 
rate in LNCaP cells that, though at low rates, increases with time and concentration.  
In the development of prostate cancer, the androgen receptor (AR) has a pivotal role. 
The AR controls and induces signalling pathways during prostate development 
(Meeks and Schaeffer 2011) and is also involved in the growth of prostate carcinoma 
due to the reactivation of androgen-induced pathways (Schaeffer et al. 2008). 
Interestingly, androgen deprivation leads to increased expression of the closely 
related HMGA1 gene (Takeuchi et al. 2012). It might thus be interesting to 
investigate if a similar mechanism of increase upon androgen deprivation also exists 
for HMGA2 expression. HMGA2 could then, following the androgen refraction of 
LNCaP cells, lead to their further dedifferentiation as they retained prostate cell 
specific properties and represent early stages of prostate cancer (Dozmorov et al. 
2009).  
As to HMGA2, let-7 c, a member of the let-7 miRNA family and acting as negative 
regulator, was found to be down-regulated in human prostate cancer, suggesting 
up-regulation and thus a role for HMGA2 in this tumour type as well (Nadiminty et al. 
2012). As the cell line LNCaP was found to display high levels of let-7c, an inverse 
correlation with HMGA2 mRNA levels can be guessed. Interestingly, HMGA2 mRNA 
levels did not respond to abrogation of miRNA processing by DICER1 silencing. The 
HMGA2 suppressive mechanism in the LNCaP cell line still needs further exploration, 
as the let-7 family does not seem to be the main actor in the abrogation of HMGA2 
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expression therein. This is in contrast to HeLa cells that also display barely 
detectable HMGA2 expression but in which increased mature mRNA could be 
detected after DICER1 silencing (Lee and Dutta 2007).  
Due to the four apparently normal chromosomes 12 bearing the HMGA2 locus as 
detected by FISH analysis, epigenetic mechanisms like methylation are also potential 
silencing possibilities. Treatment with the demethylating agent 5-AdC caused a low, 
but reliably detectable mRNA level of HMGA2 pointing to DNA methylation being 
involved in its silencing. Data concerning the methylation/acetylation status of the 
HMGA2 gene locus regulating its expression are found sparsely in the literature. 
Murine Hmga2 responds to acetylation, as the histone deacetylase inhibitor TSA 
represses its transcription (Ferguson et al. 2003). Introduction of CpG islands as well 
as differential methylation of HMGA2-CpG-sites and those surrounding HMGA2 
establishing an association with type II diabetes was found in human pancreatic 
islets, but no mRNA alterations due to differential methylation were reported (Dayeh 
et al. 2013).  
As cell viability was strongly reduced in the empty vector control as well is in the cells 
transfected with the WT HMGA2 insert, HMGA2 expression seems to be harmful to 
LNCaP cells which was confirmed by incubation with recombinant HMGA2 making 
HMGA2 silencing reasonable. The cell line LNCaP might hence constitute a valuable 
tool to explore the mechanisms responsible for HMGA2 silencing, as it seems to 
deviate from the main mechanism, i.e. knock down by regulating miRNAs such as 
e.g. the main actor, the let-7 family. Further investigation should be assigned to the 
consequences of HMGA2 expression and the influence of the protein in the cell line 
LNCaP as well as possible carry over to other malignant tumours without 
endogenous HMGA2.  
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4. Discussion 
 
The architectural transcription factor HMGA2 is expressed during embryonic 
development and impacts a variety of cellular functions such as cell differentiation, 
proliferation, DNA repair and others. In the adult, its reactivation is a critical point in 
tumourigenesis, since HMGA2 accounts as a proto-oncogene favourable to tumour 
initiation and progression. Hence, comprehension of its regulation as well as the 
mechanisms inducing dysregulated expression in already differentiated tissue and 
the consequences following HMGA2 dysregulation are of major interest, allowing the 
development of potential interventions to avoid HMGA2 dysregulation as therapeutic 
strategies in neoplasias. 
In the work presented herein, the regulation mechanisms impacting HMGA2 
expression in cells of different origin were subject of several experiments. The 
induction of HMGA2 by growth factors and its correlation with proliferation were 
examined in HUVECs and in the prostate cancer cell line PC-3 expressing 
endogenous HMGA2. Another prostate cancer cell line lacking this expression 
(LNCaP) served as a model for the impact of recombinant HMGA2 on these cells and 
the silencing mechanism responsible for the absence of HMGA2 expression therein. 
Using high-resolution aCGH, ULs with a t(12;14) were screened for common 
deletions associated with the translocation on chromosome 12.  
Angiogenesis and vascularisation are important processes in embryonic development 
associated with proliferation of endothelial cells (Humar et al. 2002) building the 
blood vessel system in the growing embryo. Blood vessel formation is also necessary 
in tumourigenesis. During tumour cell proliferation and tumour growth, cell death due 
to insufficient oxygen occurs (Brahimi-Horn and Pouysségur 2006). The so-called 
hypoxia leads to the activation of HIF1A (hypoxia inducible factor 1, alpha subunit 
(basic helix-loop-helix transcription factor)) that induces the expression of pro-
angiogenic genes like VEGFA (Pouysségur et al. 2006) finally resulting in vessel 
building to ensure nutrition and oxygen supply of the tumour. The angiogenic switch 
thus refers to the transition from pre-vascular hyperplasia to a highly vascularised 
and progressively outgrowing tumour (for review see Baeriswyl and Christofori 2009). 
Vessel building requires the proliferation and migration of endothelial cells that finally 
form a lumen to enable blood flow (Bergers and Benjamin 2003), a process that is 
supported by a variety of other growth factors, including FGFs. FGF2 is involved in 
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the proliferation and migration of HUVECs (Kitamura et al. 2013), and the same is 
true for FGF1 (Presta et al. 2005). VEGFA possesses a high angiogenic potential 
(reviewed in Ylä-Herttuala et al. 2007). As in smooth muscle cells HMGA2 was found 
to up-regulate pro-angiogenic factors like FGF2 as well as to down-regulate e.g. the 
VEGF receptor FLT1 (fms-related tyrosine kinase 1) (Borrmann 2003) being a 
negative regulator of embryonic angiogenesis (Hiratsuka et al. 2001), HMGA2 is 
suggested to contribute directly to tumour angiogenesis by supporting the 
proliferation of endothelial cells. HMGA2 expression induced by growth factors could 
hence support proliferation of endothelial cells and enhance angiogenesis during 
embryonic development as well as in tumour growth. HUVECs are a widely used cell 
type to study the angiogenic processes in vitro and were thus chosen as 
experimental model. Interestingly, FGF1 and FGF2 induced the highest HMGA2 
expression with a 2- and 2.5-fold increase in expression that correlated with a rise in 
proliferation approximately 1.8- and 1.9-fold, respectively. The lowest expression was 
induced by VEGFA, which was also linked to the weakest induction of proliferation. 
The linear correlation between HMGA2 and proliferation is supported by a R-value of 
0.96 indicating that HMGA2 might play a role in the promotion of angiogenesis by 
enhancing endothelial cell proliferation. These three growth factors all are involved in 
endothelial cell proliferation, whereat VEGFA also contributes to vascular 
permeability as one of the initial step in the building of new vessels from pre-existing 
ones (Weis and Cheresh 2005) probably explaining the weakest proliferation 
induced.  
The role of HMGA2 in cancer varies between tumour entities. HMGA2 is up-regulated 
in prostate cancer in dogs (Winkler et al. 2007), but up to date, few data are available 
concerning in vivo deregulation of HMGA2 in human prostate cancer. The amount of 
HMGA2 was found to be significantly increased in a subset of four matched tumour 
and normal tissues (Zhu et al. 2013), and in a mouse model, Hmga2 stromal 
epigenetic dysregulation was able to induce prostatic intraepithelial neoplasia (PIN) 
as preneoplastic lesions (Zong et al. 2012). The same study suggested a role for 
Hmga2 in ductal morphogenesis and regulation of epithelial differentiation, due to 
Hmga2 knock-out mice displaying a smaller prostate than wt-mice and a more than 
six-fold decrease in cell number, whereat proliferation staining with Pcna 
(proliferating cell nuclear antigen) did not display any differences (Zong et al. 2012). 
In synergy with up-regulation of the androgen receptor (AR), Hmga2 induced poorly 
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differentiated adenocarcinoma, whereas AR overexpression alone did not induce 
hyperplastic lesions (Zong et al. 2012). Furthermore, Zong et al. (2012) were able to 
show that Hmga2-modified (i.e. Hmga2 overexpressing) stromal cells induce 
epithelial proliferation, probably mediated by ß-catenin through the Wnt pathway. 
The issue of a correlation between HMGA2 expression and proliferation of tumour 
cells induced by growth factors was thus addressed using the prostate cancer cell 
line PC-3 derived from the metastasis of a poorly differentiated adenocarcinoma. This 
cell line already displays constitutive expression of HMGA2, but at a relatively 
moderate level allowing the detection of increased HMGA2 mRNA by real time RT-
PCR. Similarly to HUVECs, cells were incubated with FGF1 and PDGF-BB as well as 
with increasing concentrations of FBS for subsequent RNA isolation or determination 
of the proliferation rate by means of a BrdU-ELISA. Interestingly, the stimulation of 
HMGA2 expression by FGF1 previously observed in HUVECs as well as in 
mesenchymal cells (Ayoubi et al. 1999) did not occur as it has not been detected in 
quantitative real time RT-PCR. There was neither increased HMGA2 expression due 
to PDGF-BB nor due to various concentrations of FBS, as detected in mesenchymal 
cells (Ayoubi et al. 1999). Despite the absence of a detectable increase of HMGA2 
expression, as was observed in HUVECs, FGF1 and PDGF-BB were able to increase 
proliferation. It thus seems that a further augmentation of HMGA2 expression is not 
necessary for PC-3 to increase the proliferation rate, suggesting the amount of 
HMGA2 to be sufficient. A mechanism distinct from those in HUVECs that does not 
require further HMGA2 increase to raise proliferation of PC-3 cells is also possible. 
Besides its potential role in proliferation, HMGA2 supports further mechanisms 
maintaining and promoting tumour growth. HMGA2 e.g. up-regulates TERT 
(telomerase reverse transcriptase) maintaining telomere length essential for 
tumourigenesis (Li et al. 2011). 
A further pivotal process during epithelial cancer progression is the epithelial-
mesenchymal transition (EMT). EMT and the reverse process, MET (mesenchymal-
epithelial transition), are also fundamental processes during embryonic development 
and organ and tissue formation (for review see Thiery et al. 2009) that are reactivated 
in cancer. The transition from an epithelial to a mesenchymal cell is associated with 
changes in cell shape and a higher motile and invasive potential (Thiery et al. 2009). 
The loss of the epithelial expression marker CDH1 (cadherin 1, type 1, E-cadherin 
(epithelial), also known as E-cadherin) is a crucial step in EMT (Perl et al. 1998) and 
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associates with loosening of the tissue due to the lack of CDH1, being one of the 
proteins stabilising cell-cell adhesion and connection (Lamouille et al. 2014). 
Hallmarks of dedifferentiation of epithelial cells into a mesenchymal-like state are 
down-regulation of CDH1 and up-regulation of VIM (vimentin) and CDH2 (cadherin 2, 
type 1, N-cadherin (neuronal), also known as N-cadherin; Thiery et al. 2009). EMT is 
regulated by various transcriptions factors which offer possibilities for the influence of 
EMT by HMGA2. Likewise, repression of CDH1 is induced by transcription factors 
such as SNAI1 (snail family zinc finger 1) that are regulated by HMGA2 in 
cooperation with proteins of the Smad family (Thuault et al. 2008). The transcription 
factor Twist also regulating EMT is directly induced by HMGA2 through binding to its 
promoter (Tan et al. 2012). 
Influence of HMGA2 on EMT e.g. has been described in the PC-3 cell line (Zhu et al. 
2013) which was also used in this thesis. The study by Zhu et al. (2013) investigated 
EMT in the PC-3 as well as in the DU145 prostate cancer cell lines and revealed that 
miR-154 negatively regulates the expression of HMGA2, which usually down-
regulates CDH1, accompanied by up-regulation of the mesenchymal marker VIM 
thus a critical step of EMT. Knock-down of HMGA2 by siRNA transfection or forced 
mir-154 expression resulted in increased CDH1 and decreased VIM expression, 
suggesting that miR-154 impacts expression of these two EMT-markers mediated by 
HMGA2 silencing (Zhu et al. 2013). Consequently, HMGA2 reduction decreases the 
invasive and migratory potential of PC-3 and DU145 cells in vitro, as was also 
observed after ectopic expression of miR-154 in PC-3 cells (Zhu et al. 2013). It can 
thus be speculated that HMGA2 expression is a prerequisite enabling the 
proliferation of epithelial cells by loosening cell-cell adhesion mediated by the 
suppression of the stabilising proteins like CDH1. This would allow cell growth 
mediated by factors such as PDGF-BB and FGF1 hence promoting tumour growth. 
This is in line with the finding that HMGA2 is involved in tumour cell migration and 
invasion which has been observed in various tumours of epithelial origin. It has e.g. 
been described in hepatocellular carcinoma cell lines, where it represses CDH1 and 
induces VIM and CDH2 (Luo et al. 2013). HMGA2 expression positively correlates 
with the metastatic potential of the investigated cell lines (Luo et al. 2013). In human 
lung cancer, HMGA2 frequently is overexpressed (Meyer et al. 2007), and its knock-
down reduces cell migration (Park et al. 2010) pointing to its involvement in EMT. In 
G401 cells derived from a rhabdoid tumour of the kidney, down-regulation of 
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overexpressed HMGA2 almost abolished the invasive potential of the cell line and 
decreased proliferation (Zhang et al. 2014).  
In contrast to the PC-3 cells displaying HMGA2 expression, HMGA2 expression was 
found to be absent in the cell line LNCaP that was also derived from a prostatic 
carcinoma, but represents an early stage with retained prostate cell specific 
properties (Dozmorov et al. 2009). This suggests this cell line to be a good model to 
study the impact of HMGA2 in vitro. Interestingly, application of increasing 
concentrations of recombinant HMGA2 protein resulted in increased cell death and a 
reduction of viable cells, as determined by cytotoxicity and viability assay. The 
apoptosis rate increased slightly after 48 h, but it remained at a relatively stable level 
after 24 h. The reasons for the toxic effect of HMGA2 on LNCaP cells are unclear. So 
far, HMGA2 mainly has been described to protect against DNA-damaging drugs 
(Summer et al. 2009; Palmieri et al. 2011; Yu et al. 2014). An explanation may be 
found in the comparison between HMGA2 and HMGA1a and HMGA1b, splice 
variants derived from the closely related HMGA1 gene: in a normal rat thyroid cell 
line, HMGA1b transfected cells were unable to step through the cell cycle and 
instead stopped replicating at G2-M phase and underwent apoptosis, with similar 
effects for the HMGA1a isoform (Fedele et al. 2001). Though the cell line LNCaP has 
been derived from a malignant tumour, the cells show strictly abrogated HMGA2 
expression, leading to a lack of detection in sensitive methods such as quantitative 
real time RT-PCR. This may suggest that, comparably to HMGA1, HMGA2 
expression would severely perturb the progression through the cell cycle leading to 
increased cell death and, to a lower extend, apoptosis, as was shown by incubation 
with the recombinant HMGA2 protein. It is unclear if the primary tumour developed 
with or without expression of HMGA2, but its expression in the derived cell line 
hampers survival, despite proliferation promoting and protective properties in other 
cell lines. It would be interesting to investigate a potential correlation between the 
androgen-dependence of prostate cancer cells and their expression of HMGA2, as 
LNCaP cells depending on androgens have abrogated HMGA2 expression that is on 
the contrary high in the androgen-independent PC-3 cells. In prostate cancer cells, 
the development of androgen independence is associated with the expression of 
HMGA1 maintaining cell growth of androgen-deprived or -independent cells 
(Takeuchi et al. 2012). A similar mechanism could also be possible for HMGA2. 
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The abrogation of HMGA2 expression leads to the question of the silencing 
mechanism with which LNCaP cells achieve the complete knock-down of HMGA2. At 
the post-transcriptional level, gene regulation is impacted by miRNAs being 
endogenous, non-coding small RNA molecules with a final size of ~21-23 nucleotides 
(for detailed review see Rana 2007). Similar to classic oncogenes, particular miRNAs 
can enhance tumour formation by suppressing target genes functioning as tumour 
suppressors and vice versa, miRNAs inhibit tumour growth by the suppression of 
oncogenes (Esquela-Kerscher and Slack 2006). 
The regulation by miRNAs plays a central role in the control of HMGA2 expression. 
The HMGA2 3’UTR has been found to negatively regulate gene expression (Ayoubi 
et al. 1999; Borrmann et al. 2003) and was later shown to harbour seven let-7 
binding sequences (Mayr et al. 2007; Lee and Dutta 2007). The let-7 miRNA being 
described for the first time in the nematode Caenorhabditis elegans, which was also 
the first organism at all in which RNA induced gene silencing was demonstrated (Fire 
1999), is known to cause destabilisation and degradation of its target mRNAs (Bagga 
et al. 2005), including HMGA2. Inverse correlation between HMGA2 mRNA and 
members of the let-7 family, that comprises 13 members in humans (Roush and 
Slack 2008), is found during development, with let-7 in the late stages of animal 
development (Pasquinelli et al. 2000) and HMGA2 in the early ones (Hirning-Folz et 
al. 1998). During the past years, HMGA2 has been shown to be targeted by some 
miRNAs. Among these are e.g. the previously mentioned let-7 family with the 
miRNAs let-7 (Mayr et al. 2007) and miR-98 belonging to the same family (Hebert et 
al. 2007), miR-10a* and miR-21 (Zhu et al. 2013), miR-23b (Leone et al. 2014), miR-
26a (Zhou et al. 2014), miR-142-3p (Chiou et al. 2013), miR-154 (Zhu et al. 2013), 
miR-365 (Qi et al. 2012) and others. 
HMGA2 overexpression often is caused by the loss of regulated gene expression of 
the miRNAs themselves resulting in expression or silencing of the respective miRNA 
genes. The let-7 miRNA family e.g. is regulated by LIN28A (lin-28 homolog A (C. 
elegans) and LIN28B (lin-28 homolog B (C. elegans)) via different regulatory 
mechanisms impeding let-7 maturation (Piskounova et al. 2011). Consequently, 
misexpression of LIN28 is found in tumours with impact on let-7 expression as well 
as on the let-7 target genes. LIN28A and LIN28B are overexpressed followed by 
down-regulated let-7 expression and thus increased HMGA2 expression in e.g. oral 
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squamous cell carcinoma (Wu et al. 2013), glioblastoma (Mao et al. 2013) and head 
and neck cancer (Alajez et al. 2012). 
In prostate cancer, the let-7 family as well as other miRNAs were found to be down-
regulated in several studies (Ozen et al. 2008; Nadiminty et al. 2012; Schubert et al. 
2013). The most recent one found let-7b to function as a prognostic marker that also 
targets HMGA1 (Schubert et al. 2013). Dysregulation of miRNA expression might 
play a role in the up-regulation of HMGA2 gene expression in the prostate carcinoma 
cell line PC-3, as let-7c and let-7b are down-regulated therein (Nadiminty et al. 2012; 
Schubert et al. 2013).  
Interestingly, HMGA2 is in competition with other let-7 targets, influencing the 
expression thereof independently from its activity as a transcription factor by 
displacing them from the Ago-complex, as described in lung cancer cells (Kumar et 
al. 2014). From a number of 34 putative targets, 13 were suppressed by Hmga2 
depletion (Kumar et al. 2014). Six of these targets could be rescued by wt Hmga2 
and Hmga2 with mutated start codon, being thus identified as ceRNA (competing 
endogenous RNA) targets, whereat seven could be rescued by wt Hmga2 only, thus 
being classified as transcriptional targets (Kumar et al. 2014). Among the ceRNA 
targets were genes such as, amongst others, Tgfbr3 (transforming growth factor, 
beta receptor III) and, interestingly, Hmga1 (Kumar et al. 2014). HMGA1 just recently 
was found to be targeted by the let-7 miRNAs so that a synergistic effect of HMGA1 
and HMGA2 up-regulation is imaginable. Double-knock out of Hmga1 and Hmga2 in 
mice resulted in a “superpygmy” phenotype displaying reduced vitality and an 
extremely small size of 75 % of wt mice (Federico et al. 2014), whereat the body size 
of Hmga2 knock-out mice was reduced about 60 % only (Zhou et al. 1995).  
As HMGA2 mRNA was not detectable in the LNCaP cell line though it displays a 
hypotetraploid karyotype including four apparently normal chromosomes 12 bearing 
the HMGA2 locus, miRNAs are suspected to be responsible for mRNA repression. In 
contrast to the PC-3 cell line, LNCaP cells exhibit higher levels of let-7 miRNAs that 
could thus be part of the HMGA2 silencing program in this cell line (Nadiminty et al. 
2012; Schubert et al. 2013). Suppression of DICER1 which represents an essential 
part in miRNA biogenesis by siRNA would thus lead to increased HMGA2 mRNA 
amounts due to the lack of miRNA degradation. This would thus make HMGA2 
detectable by quantitative PCR. 
Discussion 
- 65 - 
Interestingly, the performed DICER1 knock-down did not lead to detectable HMGA2 
expression in LNCaP cells as expected if HMGA2 was silenced by miRNA regulation 
and which was shown in HeLa cells (Lee and Dutta 2007). Therefore, alternative 
mechanisms being responsible for the lack of measurable HMGA2 mRNA needed to 
be considered. Epigenetic mechanisms impacting gene expression at the 
transcriptional level as e.g. methylation of CpG island and histone acetylation are 
valuable candidates for gene silencing. Methylation of CpG promoter islands leads to 
decreased gene expression and histone acetylation changes the overall charge of 
the nucleosome being composed of several histone proteins from positive to neutral 
leading to a more relaxed DNA structure that is now accessible for transcription 
factors.  
The treatment of LNCaP cells with increasing concentrations of the DNA 
methyltransferase inhibitor 5-AdC actually resulted in the detection of HMGA2 mRNA 
transcripts, though the amount was still at a very low level. The level of HMGA2 
mRNA amounted to 0.31-, 0.43- and 0.38-fold of that of the calibrator MCF-7 which 
was used due to the lack of HMGA2 expression in the non-treated control. A 
0.29-fold expression was yielded by simultaneous treatment with the histone 
deacetylase inhibitor TSA, while TSA alone did not result in HMGA2 expression.  
Up to date, the methylation status of the HMGA2 gene and its genomic vicinity is not 
well documented. Given the cytotoxic potential of HMGA2 in LNCaP cells, silencing 
of HMGA2 still is favourable for their overall survival. The tight silencing of the 
HMGA2 gene shows that cells in general are in charge of a variety of mechanisms to 
determine a favourable gene expression profile. Though representing the opposite 
situation, namely the protection of HMGA2 mRNA from being introduced into miRNA 
RISC, the ability to accurately control gene expression is underlined by the recent 
finding that HMGA2 mRNA is protected in IGF2BP3 (insulin-like growth factor 2 
mRNA binding protein 3) RNP (ribonucleoprotein) granules (Jønson et al. 2014). 
Besides HMGA2 mRNA, other let-7 target mRNAs like that coding for LIN28B, 
suppressing let-7 maturation, are also stored and protected in these “safe houses” 
thus increasing the amount of oncogenes during tumour growth (Jønson et al. 2014). 
It is unclear, if the HMGA2 promoter region itself is demethylated upon 5-AdC 
treatment, or other genes are demethylated, which in turn activate HMGA2. 
Nonetheless, HMGA2 mRNA levels still were very low. Concerning HMGA2 
regulation via histone deacetylation, it is known that the murine as well as the human 
Discussion 
- 66 - 
HMGA2 gene become down-regulated in NIH3T3, HeLa and F9 (derived from a 
mouse testicular teratoma) cells upon inhibition of histone deacetylases with TSA 
(Ferguson et al. 2003), confirming the lacking effect of TSA alone on treated LNCaP 
cells. It was later shown that a negatively regulating effect of HDAC inhibition in 
human umbilical cord blood-derived multipotent stem cells also was mediated by 
transcriptional activation of miRNAs miR-23a, miR-26a and miR-30a targeting 
HMGA2 (Lee et al. 2011).  
In benign mesenchymal tumours, reactivation of HMGA2 is different from that in 
malignant cancer, as HMGA2 is targeted by chromosomal aberrations 
(Schoenmakers et al. 1995; Ashar et al. 1995). In lipomas, the negatively regulating 
3’UTR (Mayr et al. 2007; Lee and Dutta 2007) is separated from the first three exons 
which become fused with exons obtained from LPP leading to a fusion protein (Petit 
et al. 1996). In contrast, the HMGA2 translocation in uterine leiomyomas targets 
different chromosomal regions than that in lipomas and, more importantly, the 
breakpoints mainly are located upstream or downstream of the HMGA2 locus 
(Schoenberg Fejzo et al. 1996; Quade et al. 2003). Uterine leiomyomas generally 
display higher HMGA2 expression when compared to the surrounding myometrium, 
but the highest expression levels can be observed in tumours carrying t(12;14) 
(Klemke et al. 2009). Thus, re-expression of HMGA2 not only due to the loss of the 
3’UTR, but also influenced by different regulatory units probably located in the 
5’ region as well (Schoenberg Fejzo et al. 1996; Quade et al. 2003), can be 
assumed. This is underlined by the presence of the 3’UTR including the complete 
let-7 binding sites in eight of 13 UL with a t(12;14) (Klemke et al. 2010). The mapping 
of the breakpoint as well as the loss of regulatory units positively affecting HMGA2 
expression should be able to provide new insights into the mechanism leading to up-
regulation by this translocation. Therefore, uterine leiomyomas bearing the t(12;14) 
translocation were chosen for investigation with aCGH enabling the detection of small 
losses associated with the translocation that otherwise seems to be balanced by 
means of conventional karyotyping due to the limited resolution. In two of the 
investigated uterine leiomyomas, a small loss that might be caused by the 
translocation was identified by visual inspection with DNA Analytics software 
(Agilent). Both potential breakpoints are located upstream of the HMGA2 locus at a 
distance of ~1.14 Mb and ~412 kb, respectively, revealing that no common region 
was affected. FISH using probes that span those regions that were indicated as 
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deleted or a custom-made array with a narrower probe spacing of this region would 
be a useful tool for the confirmation of those potential breakpoint-associated 
deletions. The localisation of the potential breakpoints upstream of HMGA2 is in line 
with the finding that re-expression of HMGA2 due to loss of the 3’UTR and the 
resulting missing influence of let-7 can be excluded for at least 2 of the ULs 
investigated herein, as gene expression analysis using real-time PCR for full length 
HMGA2 as well as the 3’UTR only did not reveal differential expression for these two 
sequences (Klemke et al. 2010). Only one of these tumours displayed higher 
expression for exons 1-2 than for the 3’UTR pointing to a potential further intragenic 
breakpoint in at least some of the cells, though there are larger differences between 
both assays in the tumour set investigated (Klemke et al. 2010).  
The up-regulation of HMGA2 hence is not accompanied by the deletion of a common 
region containing negatively regulating elements. Also in discussion is the activation 
of HMGA2 through this translocation because of an enhancing region on 
chromosome 14 provided by the translocation partner RAD51B (Mehine et al. 2013). 
The activation of HMGA2 can thus be compared to that of MYC (v-myc avian 
myelocytomatosis viral oncogene homolog) where MYC is activated through 
enhancing regions provided by the translocation partner IGH (immunoglobulin heavy 
locus; Hayday et al. 1984). In addition to the lost down-regulating influence of let-7 
expression on HMGA2, Mayr et al. (2007) propose suppression of HMGA2 fusion 
partners such as RAD51B and others that are known tumour suppressors through 
transfer of the HMGA2 3’UTR. The let-7 binding sites transferred from HMGA2 make 
their mRNA susceptible to miRNA destabilization leading to degradation of their 
mRNA target, thus enhancing tumourigenesis. Separation of the HMGA2 3’UTR and 
the CDS is a frequent finding in lipomas (Bartuma et al. 2009) and also occurs in 
uterine leiomyomas, although more rarely therein (Quade et al. 2003; Klemke et al. 
2010).  
Nevertheless, miRNAs also seem to play a role in HMGA2 dysregulation in uterine 
leiomyomas, as miR-93 and miR-106b are candidates for HMGA2 regulation that are, 
besides the well-known let-7a, down-regulated in tumours overexpressing HMGA2 
(Mello et al. 2013). MiR-93 and miR-106b are located in the chromosomal region 
7q22 (Mello et al. 2013) that is frequently deleted in uterine leiomyomas and also 
harbours the transcriptional regulator CUX1 (cut-like homeobox 1) being the target of 
7q22 aberrations (Schoenmakers et al. 2013). Furthermore, a signature of miRNA 
Discussion 
- 68 - 
expression associated with race and tumour size was revealed (Wang et al. 2007). 
Conversely, the let-7 family was found to be higher expressed in the tumour than in 
the matching myometrial tissue (Wang et al. 2007), whereat high levels were found in 
small uterine leiomyomas and low levels in larger ones, matching to the report that 
high HMGA2 expression is correlated with larger size (Rein et al. 1998; Hennig et al. 
1999). As high proliferation indexes obtained by the proliferation marker MKI67 
(marker of proliferation Ki-67) associated with higher HMGA2 expression were 
inversely correlated with let-7c expression, the hypothesis of other mechanisms 
interrupting the regulation of HMGA2 by let-7 is supported (Peng et al. 2008). Cryptic 
transcripts and point mutations in the let-7 binding sites (Peng et al. 2008) may also 
be responsible as well as shortening of the 3’UTR by alternative cleavage and 
polyadenylation (Mayr and Bartel 2009), though this mechanism for HMGA2 so far 
only has been described in serous ovarian carcinoma (He et al. 2014). By shortening 
the 3’UTR, oncogenes achieve higher mRNA stability and produce greater protein 
amounts by escaping miRNA regulation (Mayr and Bartel 2009). However, 
transcriptional activation still is a possible reason that cannot be excluded for high 
HMGA2 expression in uterine leiomyomas.  
Concluding, it can be said that re-activation of HMGA2 is a major event in both 
benign mesenchymal and malignant epithelial tumours, further enhancing 
tumourigenesis. As is shown by the results presented herein, the reasons for HMGA2 
activation and its impact on the cell type as well as its silencing differ and consist of 
multiple and different mechanisms that need specific targeting when considering 
therapy. 
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5. Summary 
 
In the work presented herein, mechanisms leading to the activation of the oncofoetal 
HMGA2 gene in benign as well as in malignant tumours have been investigated. In 
mesenchymal cells, HMGA2 expression increases upon incubation with growth 
factors such as FGF1, FGF2 and PDGF-BB. This effect was examined in HUVECs 
and in the human prostate carcinoma cell line PC-3. In HUVECs, HMGA2 increased 
in response to FGF1, FGF2 and VEGFA, with the highest increase for FGF2. VEGFA 
induced the lowest response. The proliferation of HUVECs nearly doubled in 
consequence of incubation with FGF1 or FGF2, while VEGFA induced the lowest 
increase in proliferation. A correlation coefficient of R=0.96 indicates a linear 
correlation. In contrast, HMGA2 is not inducible in the androgen-independent 
prostate cancer cell line PC-3 by incubation with PDGF-BB, FGF1 or FBS, also 
containing growth factors. Proliferation increased through incubation with FGF1 or 
PDGF-BB for the 1.8- or 1.6-fold, but not in response to FBS.  
Another prostate carcinoma cell line, LNCaP, does dot display detectable HMGA2 
expression in real time RT-PCR, though it possesses four apparently normal 
chromosomes 12. It is thus a good model to study the effects of HMGA2. To avoid 
the cytotoxic consequences that occurred after transfecting the eukaryotic expression 
vector pCR3.1, these cells were incubated with increasing concentrations (1, 10 and 
100 µg/ml) of a recombinant HMGA2 protein. A cytotoxic and damaging effect of 
HMGA2 was shown as well as a dose-dependent induction of apoptosis after 48 h. 
As underlying mechanism for HMGA2 silencing in this cell line, miRNAs being huge 
players in the post-transcriptional regulation seem unlikely, as knock-down by siRNA 
targeting DICER1, which is essential in miRNA processing, did not lead to HMGA2 
expression. The incubation of LNCaP cells with the methyltransferase inhibitor 5-AdC 
resulted in the detection of a low amount of HMGA2 mRNA by real time RT-PCR, 
indicating the methylation of the HMGA2 gene or other activating genes.  
In benign mesenchymal tumours, HMGA2 often is affected by translocations. While 
the breakpoint in lipomas often is located in intron 3 separating the 3’UTR containing 
miRNA binding sites from the coding sequences for the functional AT-hooks leading 
to the expression of a truncated but functional protein, the breakpoints in uterine 
leiomyomas mainly are located upstream of HMGA2. This points to an activation 
mechanism distinct from that in lipomas. In two of three tumours, potential small 
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deletions upstream of HMGA2 were identified that may be caused by the 
translocation and are connected to the breakpoints. A region commonly deleted was 
not identified in the tumours investigated, suggesting expansion of the study followed 
by confirmation of the potential breakpoints using FISH probes spanning the potential 
breakpoint regions to identify the loss of potential regulatory elements in the 5’ region 
upstream of the HMGA2 gene. 
The functions as well as the regulation of HMGA2 are versatile and need to be 
considered cell-type specifically to offer a valuable and promising target in potential 
therapeutic applications.  
 
Zusammenfassung 
- 71 - 
6. Zusammenfassung 
 
In der hier vorliegenden Arbeit wurden Mechanismen, die zur Reaktivierung des 
onkofoetalen HMGA2-Gens in benignen sowie in malignen Tumoren führen, 
untersucht. In mesenchymalen Zellen wird HMGA2 nach Stimulation mit 
Wachstumsfaktoren wie FGF1 und FGF2, PDGF-BB und weiteren verstärkt 
exprimiert. Dieser Effekt wurde in HUVECs sowie in der humanen Prostatakarzinom-
Zelllinie PC-3 untersucht. Hierbei zeigte sich, dass HMGA2 in HUVECs durch FGF1, 
FGF2 und VEGFA induzierbar ist, wobei FGF2 den größten Effekt erreichte. VEGFA 
induzierte den geringsten, nicht-signifikanten Anstieg in der HMGA2-Expression. Die 
Proliferation der HUVECs verdoppelte sich nahezu in Folge der Inkubation mit FGF1 
oder FGF2, während VEGFA hier ebenfalls die geringste Steigerung erzielte. Ein 
Korrelationseffizient von R=0,96 zeugt hier von einer linearen Korrelation. Im 
Gegensatz dazu ist HMGA2 in der Androgen-unabhängigen PC-3 Zelllinie nicht mehr 
durch die Inkubation mit PDGF-BB und FGF1 sowie durch FBS, das ebenfalls 
Wachstumsfaktoren enthält, induzierbar. Eine erhöhte Proliferation um das 1,8- und 
1,6-fache wurde durch FGF1 und PDGF-BB ausgelöst, nicht aber durch FBS.  
Eine weitere Prostatakarzinom-Zelllinie, LNCaP, weist im Gegensatz zu PC-3 keine 
mittels Real-Time RT-PCR detektierbare HMGA2-Expression auf, obwohl sie über 
vier augenscheinlich normale Chromosomen 12 verfügt und bietet sich somit als 
gutes Modell zur Studie der Auswirkungen von HMGA2 an. Um die ermittelten 
zytotoxischen Folgen einer Transfektion mit dem eukaryotischen Expressionsvektor 
pCR3.1 zu vermeiden, wurden diese Zellen in Medium mit verschiedenen 
Konzentrationen (1, 10 und 100 µg/ml) rekombinanten HMGA2s gehalten. In Folge 
dessen zeigte sich, dass HMGA2 auf LNCaP-Zellen eine zytotoxische und Viabilitäts-
senkende Wirkung hat und zudem nach 48 h Inkubationszeit dosisabhängig 
Apoptose auslöst. Als zu Grunde liegender Mechanismus des strikten Silencings in 
dieser Zelllinie scheint die Regulation mittels miRNAs, die eine große Rolle in der 
post-transkriptionellen Regulierung spielen, unwahrscheinlich, da ein Knock-Down 
mit Hilfe von siRNAs gegen DICER1, das essentiell für die miRNA-Prozessierung ist, 
keine Expression des HMGA2-Gens nach sich zog. Durch die Inkubation mit dem 
Methyltransferase-Inhibitor 5-AdC konnte eine, wenn auch geringe, Menge an 
HMGA2-mRNA detektiert werden, was auf eine Methylierung des HMGA2-Gens oder 
anderer, aktivierender Gene hinweist.  
Zusammenfassung 
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In benignen mesenchymalen Tumoren ist häufig das HMGA2-Gen von 
Translokationen betroffen. Während in Lipomen der 3’UTR mit den miRNA-
Bindestellen durch den Bruchpunkt in Intron 3 von der kodierenden Sequenz für die 
funktionellen AT-Hooks getrennt wird, und ein trunkiertes, aber funktionales Protein 
exprimiert wird, liegen die Bruchpunkte in Uterus-Leiomyomen größtenteils 
stromaufwärts von HMGA2. Dies deutet auf einen anderen Aktivierungs-
mechanismus als den in Lipomen hin. Mittels aCGH konnte hier in zwei von drei 
Tumoren mögliche kleine Deletionen stromaufwärts von HMGA2 gefunden werden, 
die potentiell durch die Translokation verursacht wurden und den Bruchpunkt 
möglicherweise begleiten. Es konnte jedoch keine gemeinsame Region in den 
untersuchten Tumoren festgestellt werden. Hier bietet sich eine Ausweitung der 
Studie mit anschließender Überprüfung der potentiellen Bruchpunkte mittels FISH an, 
um den Verlust von eventuellen negativen Regulatoren stromaufwärts der 5’-Region 
von HMGA2 zu identifizieren 
Zusammenfassend kann gesagt werden, dass sowohl die Funktionen als auch die 
Regulationsmechanismen von HMGA2 vielseitig sind, und daher Zelltyp-spezifisch 
betrachtet werden sollten, um ein valides und vielversprechendes Ziel in potentiellen 
therapeutischen Anwendungen zu bieten.  
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8. Abbreviations 
 
5-AdC    5-aza-2′-deoxycytidine 
aCGH    array based comparative genomic hybridisation 
ATM    ataxia telangiectasia mutated 
ATR    ataxia telangiectasia and Rad3 related 
bp    base pair 
BrdU    5-bromo-2’-deoxyuridine 
CDH1    cadherin 1, type 1, E-cadherin (epithelial) 
CDH2    cadherin 2, type 1, N-cadherin (neuronal) 
cDNA    complementary deoxyribonucleic acid 
CDS    coding sequence 
ceRNA   competing endogenous ribonucleic acid 
CHEK1   checkpoint kinase 1 
CpG    cytosine phosphate guanine 
CTNNB1   catenin (cadherin-associated protein), beta 1, 88kDa 
CUX1    cut-like homeobox 1 
DAPI    4’,6-diamidino-2-phenyindole 
DICER1   dicer 1, ribonuclease type III 
DNA    deoxyribonucleic acid 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO   dimethyl sulfoxide 
DSB    double strand break 
E2F1    E2F transcription factor 1 
EBM-2   endothelial basal medium-2 
EGM-2   endothelial growth medium-2 
ELISA    enzyme-linked immunosorbent assay 
EMEM   Eagle's Minimum Essential Medium 
EMT    epithelial-mesenchymal transition 
ERCC1 excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes over-
lapping antisense sequence) 
FBS    foetal bovine serum 
FGF1    fibroblast growth factor 1 (acidic) 
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FGF2    fibroblast growth factor 2 (basic) 
FLT1    fms-related tyrosine kinase 1 
GF    growth factor 
h    hour 
HDAC1   histone deacetylase 1 
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-loop-
helix transcription factor) 
HMGA1   high mobility group AT-hook 1 
HMGA2   high mobility group AT-hook 2 
HMGIC high-mobility group (nonhistone chromosomal) protein 
isoform I-C 
HMGIY high-mobility group (nonhistone chromosomal) protein 
isoforms I and Y 
HPRT1   hypoxanthine phosphoribosyltransferase 1 
HUVEC   human umbilical vein endothelial cell 
IGF2BP2   insulin-like growth factor 2 mRNA binding protein 2 
IGF2BP3   insulin-like growth factor 2 mRNA binding protein 3 
JunB    jun B proto-oncogene 
kDa    kilodalton 
KRAS    v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LDH    lactate dehydrogenase 
let-7 microRNA let-7 
LIN28A lin-28 homolog A (C. elegans) 
LIN28B lin-28 homolog B (C. elegans) 
LPP LIM domain containing preferred translocation partner in 
lipoma 
MET mesenchymal-epithelial transition 
min    minute 
miRNA   micro ribonucleic acid 
MIRLET7   microRNA let-7 
M-MLV   Moloney murine leukaemia virus 
mg    milligram 
MKI67   marker of proliferation Ki-67 
ml    millilitre 
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mRNA   messenger ribonucleic acid 
MYC    v-myc avian myelocytomatosis viral oncogene homolog 
NaCl    sodium chloride 
NF-κB nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 
ng    nanogram 
nt    nucleotide 
ORF    open reading frame 
PBS    phosphate buffered saline 
PAC    phage artificial chromosome 
PAGE    polyacrylamide gel electrophoresis 
Pcna    proliferating cell nuclear antigen 
PCR    polymerase chain reaction 
PDGF-BB   platelet-derived growth factor beta polypeptide 
pRB    retinoblastoma protein 
PTM    post-translational modification 
RAD51B   RAD51 paralog B  
RISC    RNA-induced silencing complex 
RNA    ribonucleic acid 
RNP    ribonucleoprotein 
rpm    rotations per minute 
RPMI 1640   Roswell Park Memorial Institute 1640 
RT    reverse transcription 
sec    second 
Smad    Smad family member 
SNAI1   snail family zinc finger 1 
SNP    single nucleotide polymorphism 
SSC    standard saline citrate 
TERT    telomerase reverse transcriptase 
TGF-beta-1   transforming growth factor beta-1 
TGFR2   transforming growth factor-beta type 2 
Tgfbr3   transforming growth factor, beta receptor III 
u    unit 
UL    uterine leiomyoma 
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UTR    untranslated region 
VEGFA   vascular endothelial growth factor A 
VIM    vimentim 
WNT    wingless-type MMTV integration site family 
ZCCHC11   zinc finger, CCHC domain containing 11 
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